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INTRODUCTION
Imagine the following situation: Dr. Jane Smith is a thirty-five year-old neurosurgeon
who entered private practice three years ago upon completion of her training. She has an
annual income of $200,000. One day, while crossing the street from the doctors' parking
lot to the hospital, she is run over by a Zippy Express delivery truck, whose unlicensed,
intoxicated driver was speeding to a delivery and failed to stop for a red light. As a result
of the accident, Dr. Smith has become quadriplegic and will be unable to perform surgery
again.
In a negligence action against Zippy Express, a key component of Dr. Smith's
economic damages is her lost income. Assuming she would have been able to work for
thirty more years, with an income of $200,000 per year, this would amount to six million
in current dollars, exclusive of projected earnings increases, merely for lost income.
Suppose, however, that Dr. Smith is in the unaffected, presymptomatic stage of
Huntington's disease, amyotrophic lateral sclerosis, or some other late-onset genetic
disorder. Further suppose that experts will testify that, in all likelihood, irrespective of
the accident, she would not have been able to practice medicine beyond age forty-five and
that her life expectancy is fifty years. Applying traditional damages principles, this
information would reduce her recovery for economic injury by at least four million
dollars.
Zippy Express and its insurers therefore would have a great economic incentive to
discover information about Dr. Smith's genetic profile and to introduce this information
at trial. Should the defendants be able to discover this information by obtaining access
to Dr. Smith's medical records? Should they be able to obtain a court order directing Dr.
Smith to submit to genetic testing? Should it matter whether genetic testing previously
had been performed on Dr. Smith or whether there was something in her family or
medical history to suspect a genetic disorder? Should it matter whether Dr. Smith was
suspected of having a genetic risk of a monogenic disorder, such as Huntington's disease,
or a multifactorial disorder, such as cancer? What effect, if any, should be given to the
penetrance, variable expressivity, and treatability of the disorder? Should it matter if Dr.
Smith objects to genetic testing?
The preceding scenario and the resulting questions have the potential to become
commonplace. Without thoughtful judicial or legislative intervention, the combination
of exponential increases in genetic information generated by the Human Genome Project
and overwhelming economic incentives of defendants to limit their liability in personal
injury cases will give rise to irresistible pressures to include genetic information in civil
litigation. Conceivably, in every case in which the plaintiff seeks to recover for
permanent or long-term disability or lost future earnings, regardless of the legal theory
of the case, the defendant could seek to discover the plaintiffs risk of premature
incapacity or mortality by obtaining genetic records or performing genetic testing.'
This Article considers the scientific, legal, and policy issues underlying the use of
genetic information to determine damages in personal injury litigation. A related and
important set of issues surrounds the admissibility of genetic information at trial. Because
1. The life expectancy of the injured party is also relevant when the plaintiff seeks damages for medical expenses
and pain and suffering, as well as in wrongful death actions.
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the legal standards for discovery of evidence are generally broader than for its
admissibility, and because of a desire to keep this complicated subject within manageable
proportions, this Article is limited to the issue of discovery of genetic information.
Part I discusses the Human Genome Project and the growing ability of medical science
to predict the risk of an individual's future health. It describes several serious, late-onset
genetic conditions that could be relevant in personal injury litigation. It also discusses
the scientific limitations on our ability to predict future health status based on genetic
information. Part II contains a discussion of the general law of damages for lost future
earnings in personal injury. It includes a discussion of how evidence of the plaintiff's
preinjury medical condition may affect these damages. Part III considers the
circumstances under which a defendant may obtain discovery of a plaintiff's medical
records pursuant to Rule 26 of the Federal Rules of Civil Procedure and its state analogs.
Part IV continues with a discussion of when a defendant may compel the physical
examination of a plaintiff pursuant to Rule 35 of the Federal Rules of Civil Procedure and
its state analogs. Part V considers the public policy implications of using a personal
injury plaintiff's genetic profile to assess damages. The public policy concerns not only
implicate privacy and confidentiality issues, but also the possible effects on clinical
genetics and the willingness of at-risk individuals to undergo genetic testing when the
records are discoverable. It contrasts the public health and public policy interests in the
primary (i.e., health care) and secondary (i.e., litigation) uses of genetic information.
Part VI proposes three alternatives designed to promote the plaintiffs interests in
privacy and confidentiality, the defendant's interest in avoiding overcompensation, the
judiciary's interest in avoiding complexity in litigation, and the public's interest in the
public health and the conservation of health resources. The three suggested alternatives
involve, from most modest to most drastic: (1) the use of protective orders pursuant to
Rule 26(c) of the Federal Rules of Civil Procedure to limit discovery of genetic
information and bar physical examinations; (2) a new statute protecting the
confidentiality of genetic information; and (3) a total restructuring of the payment of
damages by enacting a variable periodic payment of damages statute. This Article
concludes by noting the imminence and potential magnitude of the issue. It urges a
prompt and thorough discussion of the proposed alternatives, as well as others, to avoid
the misuse of genetic information in litigation.
I. THE GROWTH OF GENETIC PREDICTION
The rapid expansion of genetic understanding and technology during the 1980's made
it realistic to consider the ambitious undertaking of mapping2 and sequencing' the entire
human genome.4 In 1990, the Human Genome Project officially began. Although not a
2. Gene mapping involves determining the relative locations of different genes on chromosomes. CONGRESS OF
THE UNITED STATES, OFFICE OF TECHNOLOGY ASSESSMENT, CYSTIC FIBROSIS AND DNA TESTS: IMPLICATIONS OF
CARRIER SCREENING 280 (1992) [hereinafter CYSTIC FIBROSIS AND DNA TESTS].
3. Gene sequencing refers to a "[dletermination of the order of nucleotides (base sequences) in a DNA or RNA
molecule or the order of amino acids in a protein." NATIONAL INSTITUTES OF HEALTH, NATIONAL CENTER FOR HUMAN
GENOME RESEARCH, PROGRESS REPORT-FISCAL YEARS 1991 AND 1992, at A-23 (1993) [hereinafter PROGRESS
REPORT].
4. A genome is all the genetic material in the chromosomes of a particular organism; its size is generally given as
its total number of base pairs. WEBSTER'S THIRD NEW INTERNATIONAL DICTIONARY 947 (1981). See generally Victor
A. McKusick, Mapping andSequncing the Human Genome, 320 NEW ENG. J. MED. 910 (1989); James D. Watson, The
Huntat Genome Project: Past, Present, mid Future, 248 SCIENCE 44 (1990).
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single project but rather an amalgam of international research efforts, the Human Genome
Project is expected to last fifteen years and cost about three billion dollars. 5
When the effort began, there was great concern over whether the goals and timetable
of the project were feasible.6 By the end of 1993, however, the first "rough"
comprehensive map of the human genome was announced, well ahead of schedule.7 By
the spring of 1995, the first large-scale sequencing effort had begun. It is now reasonable
to assume that the mapping and sequencing of the human genome envisioned by the
project will be completed by or before the year 2005.
The first breakthroughs came in locating the genes responsible for many of the most
common monogenic disorders. By July, 1995, scientists had localized 14,244
polymorphisms on specific regions of chromosomes9 and had identified 1116 disease-
related genes at 909 loci. 0 Some of the disease genes identified include genes for cystic
fibrosis," Duchenne muscular dystrophy, fragile X syndrome,'3 hemochromatosis, 4
hemophilia A," Lesch-Nyhan syndrome, 6  neurofibromatosis-type I,'1 and
retinoblastoma.'5
5. For a general discussion of the history of the Human Genome Project, see JERRY E. BISHOP & MICHAEL
WALDHOLZ, GENOME: THE STORY OF OUR ASTONISHING ATTEMPT TO MAP ALL THE GENES IN THE HUMAN BODY
(1990); ROBERT M. COOK-DEEGAN, THE GENE WARS: SCIENCE, POLITICS, AND THE HUMAN GENOME (1994); JOEL
DAVIS, MAPPING THE CODE: THE HUMAN GENOME PROJECT AND THE CHOICES OF MODERN SCIENCE (1990).
6. See CONGRESS OF THE UNITED STATES, OFFICE OF TECHNOLOGY ASSESSMENT, MAPPING OUR GENES-THE
GENOME PROJECTS: HOW BIG, How FAST? 4-10 (1988).
7. Natalie Angier, Map ofAll Chromosomes to Guide Genetic Hunters, N.Y. TIMES, Dec. 16, 1993, at Al.
8. Eliot Marshall, Eniphasis TunLvfrom Mapping to Large-Scale Sequencing, 268 SCIENCE 1270 (1995); see also
Nicholas Wade, Rapid Gains Are Reported on Genome, N.Y. TIMES, Sept. 28, 1995, at A13, A24 (reporting that
sequencing may be 99% completed by 2002). See generally Rachel Nowak, Bacterial Genome Sequence Bagged, 269
SCIENCE 468 (1995) (discussing completion of first genome of living organism and suggesting that techniques used on
microorganisms may be used for human genome).
9. Genome Data Base, Johns Hopkins University (on-line) (July 26, 1995).
10. Mendelian Inheritance in Man, Johns Hopkins University (on-line) (July 26, 1995).
11. Cystic fibrosis is an autosomal recessive disorder that usually begins in infancy and is characterized by chronic
respiratory infection, pancreatic insufficiency, abnormally viscid mucous secretions, and susceptibility to thermal stress.
THE MERCK MANUAL OF DIAGNOSIS AND THERAPY 2206 (16th ed. 1992) [hereinafter MERCK MANUAL]; see Bat-Sheva
Kerem et al., Identification of the Cystic Fibrosis Gene: Genetic Analysis, 245 SCIENCE 1073 (1989).
12. Duchenne muscular dystrophy is an X-linked disorder resulting from a mutation in the gene that encodes
dystrophin, which causes progressive weakness and degeneration of muscle fibers. VICTOR A. McKUSICK, MENDELIAN
INHERITANCE IN MAN: CATALOGS OF AurOSOMAL DOMINANT, AUrOSOMAL RECESSIVE, AND X-LINKED PHENOTYPES
1922 (10th ed. 1992); see M. Koenig et al., Complete Cloning of tie Duchenne Muscular Dystrophy (DMD) cDNA and
Preliminary Genomic Organization of the DMD Geie in Normnal and Affected Individuals, 50 CELL 509 (1987).
13. Fragile X syndrome, an X-linked disorder, is the most common form ofinherited mental retardation. McKUSICIK,
supra note 12, at 1904; see EJ. Kremer et al., Mapping of DNA Instability at the Fragile Xto a Trinucleotide Repeat
Sequence p(CGG)n, 252 SCIENCE 1711 (1991).
14. Hemochromatosis is an autosomal recessive disorder in which an increasing overload of iron in the liver leads
to cirrhosis of the liver, diabetes, hypermelanomic pigmentation of the skin, and heart failure. It is rare before middle age.
MCKUSICK, supra note 12, at 1435; see E.C. Jazwinska et al., Localization of the Hemochroniatosis Gene Close to
D6SI05,53 AM. J. HUM. GENETICS 347 (1993).
15. Hemophilia A is an X-linked disorder that results in a hereditary defect in antihemophilic globulin (factor ViII).
The deficiency in coagulation factors leads to bleeding disorders that begin in early childhood. MCKUSICK, supra note
12, at 1848; see Jane Gitschier et al., Characterization of the Hunan Factor VIII Gene, 312 NATURE 326 (1984).
16. Lesch-Nyhan syndrome is an X-linked disorder characterized by mental retardation, spastic cerebral palsy,
choreoathetosis, uric acid urinary stones, and self-destructive biting of fingers and lips. MCKUsICK, stpra note 12, at 1873;
see Al Edwards et al., Automated DNA Sequencing of the Humn HPRTLocus, 6 GENOMICS 593 (1990).
17. Neurofibromatosis type is an autosomal dominant disorder. Patients may exhibit a variety of symptoms, but
the only consistent ones are cafe-au-lait spots and fibromatous skin tumors. It is associated with a tendency to malignant
degeneration of the neurofibromas. McKUsICK, stpra note 12, at 759; see Richard M. Cawthon et al., A MajorSegment
of the Neurofibronatosly Type I Gene: cDNA Sequence, Genomic Structure. and Point Mutations, 62 CELL 193 (1990).
18. Reinoblastoma, an autosomal recessive disorder, is a malignant tumor that arises from the nuclear layers of the
retina. It is usually diagnosed before age two and, if diagnosed early, has a cure rate exceeding 80%; however, treatment
usually requires removal of much of the optic nerve. MERCK MANUAL, supra note 11, at 2205; see Stephen H. Friend et
al., A Human DNA Segment with Properties of the Gene That Predisposes to Retinoblastomo and Osteosarcoma, 323
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During 1994 and 1995, major new advances were announced in the search for cancer-
causing genes. Genes responsible for a portion of breast, 9 colon,20 ovarian, 21 prostate,22
and other cancers were discovered. In addition to the previously discovered p53'l tumor
suppressor gene, the ATM (ataxia telangiectasia mutated) gene24 was discovered in 1995.
Both of these genes have been associated with numerous forms of cancer. Work also has
been proceeding on the identification of genes associated with other multifactorial
disorders, such as heart disease,2 diabetes, 26 asthma,27 and rheumatoid arthritis, 2 as well
as various. neuropsychiatric conditions 29 and behaviors."
A number of the genes already discovered and others under investigation are associated
with adult-onset disorders. Thus, these disorders are of particular relevance to the issue
of damages in personal injury litigation. Genetic testing of an asymptomatic plaintiff
might indicate that the individual is at an increased risk of or is expected to develop a
certain disorder that would mean premature disability (and decreased earning capacity)
or death. Among the monogenic adult-onset disorders that could result in severe
disability or death are the following: acute intermittent porphyria,2' adult polycystic
NATURE 643 (1986).
19. Yoshio Miki ct al., A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCAI, 266
SCIENCE 66 (1994).
20. Richard Fishel et al., The Humt Mutator Gene Homolog MSH2 and Its Association with Hereditary
Nonpolyposis Colon Cancer, 75 CELL 1027 (1993).
21. Miki et al., supra note 19; David C. Schultz et al., Characterization of Chromosome 9 in Human Ovarian
Neoplasia Involving 9p, Including CDKoY2, 55 CANCER RES. 2150 (1995).
22. Jin-Tang Dong ct al., KNI, A Metastasis Suppressor GeneforProstate Cancer on Hunman Chromosome lip]1.2,
268 SCIENCE 884 (1995).
23. See Frederick P. li et al., Recommendations on Predictive Testingfor Germ Line p53 Mutations Among Cancer-
Prone Individuals, 84 J. NAT'L CANCER INST. 1156 (1992).
24. See Kinneret Savitsky ct al., A Single Ataxla Telangiectasia Gene with a Product Similar to P1-3 Kinase, 268
SCIENCE 1749 (1995).
25. See Ano G. Motulsky & John D. Brutzell, Genetics of Coronary Atherosclerosis, in THE GENETIC BASIS OF
COMMON DISEASES 150 (Richard A, King et al. eds., 1992).
26. See Jack L. Leahy & Aubrey E. Boyd IIl, Diabetes Genes in Non-insulin-dependent Diabetes Mellitus, 328 NEW
ENG. J. MED. 56 (1993).
27. See Dirkje S. Postrna et al., Genetic Susceptibility to Asthma-Bronchial Hyperresponsiveness Coinherited with
a Major GeneforAtopy, 333 NEW ENG. 1. MED. 894 (1995).
28. See Richard A. King, RheumatoidArthritis, in THE GENETIC BASIS OF COMMON DISEASES, supra note 25, at
596.
29. See Ying-Hui Fu et al., Variation in the CGG Repeat at the Fragile X Site Results in Genetic Instability:
Resolution of the Sherman Paradox, 67 CELL 1047 (1991) (explaining the fragile X syndrome); Peter McGuffin et al.,
Genetic Basis of Schizophrenia, 346 LANCET 678 (1995) (discussing schizophrenia).
30. See, e.g., Joseph Biederman et al., Further Evidence for Family-Genetic Risk Factors in Attention Deficit
Hyperactivity Disorder Patterns of Contorbidity in Probands atd Relatives in Psychiatrically and Pedialrically Referred
Samples, 49 ARCtIvES GEN. PSYCHIATRY 728 (1992) (discussing attention deficit hyperactivity disorder); Dean H. Hamer
ct al., A Linkage Between DNA Markers on the XChromosone andMale Sexual Orientation, 261 SCIENCE 321 (1993)
(discussing sexual orientation); Daniel Goleman, A Genetic Clue to Bed-Wetting Is Located, N.Y.TIMES, July 1, 1995,
at Al, A8 (presenting research that bed-wetting is not emotional).
31. Acute intermittent porphyria is an autosomal dominant, adult-onset disorder characterized by a variety of
neuropathic symptoms resulting from reduced levels of the heme synthesizing enzyme hydroxymethylbilane. Activation
of the disease is related to ectogenic factors such as drugs, diet, and steroid hormones. HARRISON'S PRINCIPLES OF
INTERNAL MEDICINE 2075-76, 2208 (Kurt J. Isselbacher et al. eds., 13th ed. 1994) [hereinafter HARRISON'S]; McKuSICK,
supra note 12, at 904-05.
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kidney disease type-, 32 amyotrophic lateral sclerosis,33 early-onset Alzheimer's disease,34
familial nephritis," Huntington's disease,3" Kennedy's disease, 37 Marfan syndrome,3"
myotonic dystrophy, 9 hereditary hemorrhagic telangiectasia, 40 and Wilson's disease. 4'
Many of these disorders are relatively uncommon, but the ability to perform multiplex
testing42 will make it feasible and cost-effective for defendants to test for them.
Although new genetic discoveries will greatly aid in the prediction of an individual's
future health, genetics is not a crystal ball. The information derived from genetic testing
is frequently ambiguous or not well understood. For virtually all disorders, the results
must be expressed as a likelihood that the individual will develop the disorder. Even then,
the severity or the nature of symptoms or the effect on the individual may not be known.
The imprecision surrounding genetic prognostication is related to several important
genetic concepts. These include the mode of inheritance, 43 whether it is a single gene or
32. Adult polycystic kidney disease is an autosomal dominant disorder that usually manifests itselfin the middle of
adult life. Bilateral cysts usually lead to renal insufficiency and eventual kidney failure. MERCK MANUAL, supra note I L
at 1730-31; see The European Polycystic Kidney Disease Consortium, The Polycystic Kichzey Disease I Gene Encodes
a 14kb Transcript and Lies Within a Duplicated Region on Chromosome 16,77 CELL 881 (1994).
33. Amyotrophic lateral sclerosis is an autosomal dominant disorder that is the most common form of progressive
motor neuron disease. The mean age of death is 57 years, with the course of the disease ranging from five to six years.
HARRISON'S, supra note 31, at 2280-81; McKusICK, supra note 12, at 71-72.
34. Early-onset Alzheimer's disease is an autosomal dominant disorder characterized by progressive dementia and
memory loss. The early-onset form may manifest itself between ages 30 and 40. HARRISON'S, supra note 31, at 2208; see
R. Sherrington et al., Cloning ala Gene Bearing Missense Mutations in Early-Onset Familial Alzheimer's Disease, 375
NATURE 754 (1995).
35. Familial nephritis is an autosomal dominant renal disease that is usually diagnosed in adulthood after the
appearance of proteinuria, microscopic hematuria, or hypertension. McKUSICK, supra note 12, at 755.
36. Huntington's disease (formerly called Huntington's chorea) is an autosomal dominant disorder which usually
begins to appear between ages 30 and 40. Its leading features are choreic movements and dementia of increasing severity,
with eventual death. MCKUSICK, supra note 12, at 550-53; see Huntington's Disease Collaborative Research Group, A
Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes,
72 CELL 971 (1993).
37. Kennedy's disease is an X-linked, adult-onset disorder with symptoms similar to amyotrophic lateral sclerosis.
It is characterized by progressive spinal muscular atrophy and muscular weakness. HARRISON'S, supra note 31, at 2209,
2282.
38. Marfan syndrome is an autosomal dominant disorder of fibrous connective tissue characterized by striking
pleiotropism and clinical variability. McKuSIcK, supra note 12, at 696-98. Onset may occur between the first and fifth
decade. An abnormality of the aortic media is the principal vascular defect. MERCK MANUAL, supra note 11, at 2251.
39. Myotonic dystrophy is an autosomal dominant disorder whose symptoms may include muscle wasting, cataracts,
hypogonadism, frontal balding, and anhythmia. MCKUSICK, supra note 12, at 745.
40. Hereditary hemorrhagic telangiectasia is an autosomal dominant, adult-onset disorder characterized by lesions
on the mucous membranes, face, and distal extremities. The major internal symptoms are recurrent gastrointestinal
bleeding. HARRISON's, supra note 31, at 295; McKUSICK, supra note 12, at 1064; see David W. Johnson et al., A Second
Locusfor Hereditary Hemorrhagic Telangiectasia Maps to Chromosome 12, 5 GENOME RES. 21 (1995).
41. Wilson's disease (of the Slavic variety) is an autosomal recessive disorder of late-onset. Hepatic secretion of
copper results in toxic accumulation of metal in the liver, brain, and other organs. HARRISON'S, supra note 31, at 2088;
see K. Petrukhin, Mapping, Cloning mid Genetic Characterization of the Region Containing the Wilson Disease Gene,
5 NATURE GENETICS 338 (1993).
42. Multiplex testing involves testing for several genetic markers in a single test. See ASSESSING GENETIC RISKS:
IMPLICATIONS FORHEALTH AND SOCIAL POLICY 170 (Lori B. Andrews et al. eds., 1994) [hereinafter ASSESSING GENETIC
RISKS].
43. Each normal human has 23 pairs of chromosomes; one copy of each of the 23 pairs is inherited from each parent.
Chromosomes numbered one through 22 are called autosomes. The final pair are the sex chromosomes. Because all of
the estimated 100,000 human genes are contained in each of the pairs of chromosomes, an individual inherits two copies
of each gene. CYSTIC FIBROSIS AND DNA TESm, supra note 2, at 85. "Alternative forms of the same gene are called
alleles. If the two members ofa pair of genes are alike, the individual is said to be homozygous for this allele; if they are
different, the individual is heterozygous." JAMES J. NORA & F. CLARKE FRASER, MEDICAL GENETICS: PRINCIPLES AND
PRACTICE 77 (3d ed. 1989).
There are three basic modes of inheritance for monogenic (or single gene) disorders. In autosomal dominant inheritance,
only one copy of a mutant gene can produce a trait or defect in the heterozygous individual. This may be because the
mutant gene results in the production of an abnormal protein that, even in the presence of the normal protein produced by
the normal allele, results in abnormal structure. Thus, only one copy ofan aberrant gene results in the outward expression
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multifactorial (complex) disorder," the degree of penetrance of the disorder,45 the
variable expressivity of the disorder," allelic heterogeneity, 4 allelic expansion, 4 and
genomic imprinting.
49
To begin, there is a fundamental difference between single gene (monogenic or
Mendelian) and multifactorial (polygenic) disorders. In the former, the disorder is caused
by the mutation of a single gene. Individuals who are homozygous for recessive
disorders, as well as those with mutations for autosomal dominant and X-linked
disorders, are deemed affected, although the consequences of being affected may vary
among individuals. For example, due to the high penetrance of the genetic disorder, males
with an unusual constriction of the X chromosome are said to have fragile X syndrome,
although the severity of the manifestation of the condition (mental retardation) may vary
considerably. With other monogenic disorders, because of "incomplete penetrance," even
having the gene does not mean that the individual will ever be affected.
"Problems of penetrance and expressivity become even greater in testing for complex
disorders in which multiple factors, of which the gene being tested is only one, contribute
to the causation of the disease."5 This may involve polygenic disorders, in which two or
more genes are responsible for the condition, as well as multifactorial disorders, in which
a combination of genetic and environmental factors are responsible.
Cystic fibrosis ("CF") illustrates the principle of allelic heterogeneity. This gene was
first identified in 1989, and the first mutation discovered, known as delta F508,
accounted for about seventy percent of CF mutations in individuals of European
ancestry." Within a year, over 160 mutations were discovered,52 and by 1993, over 200
mutations had been discovered. 3 Until all of the major mutations of a gene are
discovered, it will be difficult to assess the weight of any test result.
It is important to resist the temptation to put too much emphasis on the results of any
single genetic test. Genetic testing is an emerging technology. It is particularly useful in
the clinical setting to assess whether individuals who are known to be at risk of
of the gene. Ifa person with a dominant disorder mates with a person without the disorder, their children will each have
a 50% chance of inheriting the disorder. Id. at 78.
In autosomal recessive inheritance, a deleterious gene produces its disease only in the homozygote. Affected individuals
must receive one mutant gene from each parent. Because recessively inherited disorders are usually rare, almost all
homozygous affected individuals result from the mating of two heterozygous, unaffected individuals. The offspring of two
heterozygous parents have a 25% chance of being homozygous unaffected, a 50% chance of being heterozygous
unaffected, and a 25% chance of being homozygous affected. Id. at 79.
In X-linked recessive inheritance, the aberrant gene is carried on the X chromosome. The disease appears almost always
in males, whose mothers are unaffected but heterozygous carriers of the mutant gene. When a carrier female mates with
an unaffected male, 50% of daughters will be unaffected and 50% will be unaffected carriers; 50% of males will be
affected and 50% ofmales will be unaffected. Id. at 82.
44. See infra text accompanying notes 50-53.
45. See ifra text accompanying notes 50-53.
46. See infra text accompanying notes 50-53.
47. See infra text accompanying notes 50-53.
48. Allelic expansion occurs when a gene segment increases in size when it is transmitted from parent to child. The
severity of the disease is often related to the size of the allele and therefore the severity of the disorder may increase in
each generation, a phenomenon known as anticipation. ASSESSING GENETIC RisKs, supra note 42, at 63.
49. In recent years, it has been observed that for some rare disorders, the severity and nature of the disorder may
depend on which parent provided the faulty gene. This phenomenon is called genomic imprinting. Id. at 62.
50. Id. at 38.
51. Francis S. Collins, Cystic Fibrosis: Molecular Biology and 7herapeutic Implication, 256 ScIENCe 774, 774-75
(1992).
52. American Society of Human Genetics, Statement of the American Society of Humat Genetics on Cystic Fibrosis
Carrier Screening, 51 AM. J. HuM. GENETICS 1443, 1443 (1992).
53. Michael J. Walsh & Alan E. Smith, MolecularMechanisms of CFI'R Chloride Chamnel Dysftnction in Cystic
Fibrosir, 73 CELL 1251, 1251 (1993).
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monogenic disorders are unaffected, heterozygous carriers of recessive disorders, or
presymptomatic for late-onset disorders. Genetic testing is less valid scientifically when
used to predict the future health (phenotypic expression) of asymptomatic individuals.
It is even more speculative to try to predict the risk of an individual developing a
multifactorial disorder. Current genetic technology can, at best, assign a broad range of
risk. The only true test is the test of time.
II. DAMAGES FOR LOST FUTURE EARNINGS
In personal injury litigation, special damages for quantifiable losses are based on the
increased expenses and lost income caused by the injury. The latter component, lost
future earnings, is a function of income level and work life expectancy. A claim for lost
future earnings or lost earning capacity is "an estimate of lost present ability to work in
appropriate occupations, now and in the future."5" By contrast, a claim for lost earnings
refers to the loss of income from the time of injury until the date of the trial." Ordinarily,
damages for lost future earnings are only relevant after the plaintiff proves that he or she
has suffered a permanent injury. 6 Thereafter, the evidence focuses on two issues: (1) the
plaintiff's expected rate of earnings, and (2) the plaintiff s expected number of lost years
of earning capacity.57
Under the prevailing American rule, a tort victim suing for damages for permanent
injuries is permitted to base his recovery "on his prospective earnings for the balance
of his life expectancy at the time of his injury undiminished by any shortening of that
expectancy as a result of the injury.""'
The first part, rate of earnings, is relatively easy to compute. It is based on the
plaintiff's abilities, training, experience, and preinjury earnings.5 9 Prospects for wage
increases'e and loss of fringe benefit' also are considered. Loss of future earnings is not
all-or-nothing; thus; reduction of future earnings as well as inability to generate any
earnings at all are recoverable."
The second part, determining life expectancy, is already more difficult, and it is likely
to become increasingly complicated in the new era of genetics and predictive medicine.
Currently, life expectancy is based initially on standard mortality tables. These tables,
however, are merely the starting point for making a determination of life expectancy or
54. 2 DAN B. DOBBS, DOBBS LAW OF REMEDIES: DAMAGES-EQUITY-RESTrrTIrnON 362 (2d ed. 1993) (citations
omitted).
55. See Border Apparel.E., Inc. v. Guadian, 868 S.W.2d 894, 897 (Tex. Ct. App. 1993).
56. See Exxon Corp. v. Fulgham, 294 SE.2d 894, 898 (Va. 1982).
57. Post-injury life expectancy is important in calculating other damages in personal injury cases, including pain and
suffering, see In re FELA Asbestos Litig., 638 F. Supp. 107,114-15 (W.D. Va. 1986), rev'd on other grounds sub noma.,
Wingo v. Celotex Corp., 834 F.2d 375 (4th Cir. 1987); Watson v. City of Chicago, 464 N.E.2d 1100, 1103 (11. App. Ct.
1984), and medical expenses, see Smith v. United States Dep't of Veterans Affairs, 865 F. Supp. 433, 440 (N.D. Ohio
1994); Mathieu v. Imperial To Corp., 632 So. 2d 375,381-82 (La. Ct. App.), rev'don other grounds, 646 So. 2d 318 (La.
1994). These issues arc identical to those involving loss of future earnings.
58. Sea-Land Scrys., Inc. v. Gaudet, 414 U.S. 573, 594 (1974) (emphasis omitted) (quoting 2 FOWER V. HARPER
& FLEMING JAMEs, JR., THE LAW OF TORTs § 24.6, at 1293-94 (1956)). The American rule is based on the English
decision in Phillips v. London & S.W. Ry., 5 Q.B.D. 78 (C.A.), aff'g4 Q.B.D. 406 (1879).
59. See Thibodeaux v. USAA Casualty Ins. Co., 647 So. 2d 351, 360-61 (La. Ct. App. 1994).
60. Id. at 361.
61. Wingad v. John Deere & Co., 523 N.W.2d 274, 279 (Wis. Ct. App.), review denied, 527 N.W.2d 335 (Wis.
1994).
62. See Chambers v. Graybiel, 639 So. 2d 361,367-68 (La. Ct. App.), writ denied, 644 So. 2d_377 (La. 1994).
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work expectancy. "[S]uch evidence is not conclusive but merely an aid to assist [the jury]
in determining the present value of any future damages determined to be due...."I
Perhaps the earliest American case on this issue is Denman v. Johnston.6 The
defendant negligently drove a team of horses, which struck the plaintiff and caused
serious injury. Prior to the accident, however, the plaintiff was suffering from a hernia
and unspecified internal injuries. The Supreme Court of Michigan held that mortality
tables alone could not be used to determine the plaintiff's life expectancy. "[O]ther
testimony of experts would be required to show what the plaintiff's expectancy of life
would be, taking into consideration his ailments, and the effect they would probably have
to shorten his expectancy."65
The courts have permitted a wide range of information to be introduced by either party
in attempting to ascertain the plaintiff's life expectancy and work expectancy with more
precision than mortality tables. These additional factors include the plaintiff's work
history,"6 as well as past and current health, constitution, and habits.6" In a minority of
jurisdictions, mortality tables proferred by the plaintiff are deemed inadmissible if the
plaintiff had a preexisting condition, the theory being that mortality tables are based on
the lives of "healthy people."6
Under both the majority and minority approaches, evidence of the plaintiff's medical
condition before the injury is relevant to the issue of damages.6 9 By permitting the
introduction of evidence of the plaintiff's shorter life expectancy, the plaintiff is
prevented from obtaining a windfall.
It is Plaintiff's choice to pursue claims that necessitate the introduction of life
expectancy information and basic fairness dictates that Plaintiff should not be allowed
to make a potentially large recovery against [Defendant] based on an average life span
when, in reality, Plaintiff may well have a shorter than average life expectancy."
There are two types of evidence that could indicate that the plaintiff has a shorter life
expectancy than the standard mortality tables. The first type of evidence involves
previously diagnosed diseases. If the plaintiff already had been diagnosed with cancer,7'
heart disease,' or some other life-threatening illness at the time of the injury, this
evidence would be admissible to show a reduced life expectancy.' The second type of
evidence involves factors that predict the likelihood of disease which would cause
63. Brodie v. Philadelphia Transp. Co., 203 A.2d 657,660 (Pa. 1964); accordNewman v. Bl3am, 89 N.W.2d 349,
357-58 (Iowa 1958).
64. 48 N.W. 565 (Mich. 1891).
65. Id. at 568. See generally CHARLES T. McCoRMICK, HANDBOOK ON THE LAW OF DAMAGES § 86 (1935).
66. See, e.g., Bums v. Shields, 261 A.2d 161, 163 (Md. 1970) (holding that prior dismissal from employment for
making a false statement in job application was admissible to show diminished earning capacity).
67. Woolen v. Warren, 451 S.E.2d 342, 348 (N.C. Ct. App. 1994); see Smith v. Millers Mut. Ins. Co., 419 So. 2d
59, 63 (La. Ct. App.), writ denied, 422 So. 2d 155 (La. 1982); Kilmer v. Browning, 806 S.W.2d 75, 82 (Mo. Ct. App.
1991); see also EDWARD J. DEVrT Er AL, FEDERAL JURY PRACICE AND INSTRUCTONS § 85.07 (4th ed. 1987 & Supp.
1995).
68. Simon v. Smith, 470 So. 2d 941,945 (La. Ct. App.), writ denied, 476 So. 2d 353 (La. 1985); accordDraisma
v. United States, 492 F. Supp. 1317, 1329 (W.D. Mich. 1980).
69. This Article does nol deal with the issue of computing damages resulting from the defendant's aggravation of
the plaintiff's preexisting condition-the "thin skull" rule. Rather, it deals with the discovery of medical information
indicating that, notwithstanding the defendatz's conduct, the plaintiff's work expectancy or life expectancy was less than
the actuarial norm. Thus, by application of traditional apportionment principles, the defendant is responsible only for the
additional diminution in life expectancy attributable to its wrongful conduct.
70. Agosto v. Trusswal Sys. Corp., 142 F.R.D. 118, 120 (E.D. Pa. 1992).
71. City of Tampa v. Johnson, 114 So. 2d 807, 809-10 (Fla. Dist. Ct. App. 1959).
72. Simn, 470 So. 2d at 945; Sampson v. Missouri Pac. R.R., 560 S.W.2d 573, 586 (Mo. 1978).
73. See Kanelos v. Kettler, 406 F.2d 951, 956 n.30 (D.C. Cir. 1968).
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premature mortality. The courts have admitted a wide range of evidence obehavioral
factors in attempting to prove that the plaintiff had a diminished life expectancy at the
time of the injury. These factors include the plaintiff's use of drugs,74 alcohol,' or
cigarettes.76
If evidence of cigarette smoking is admissible to show that the plaintiff's life
expectancy is lessened because of the possibility of lung cancer, emphysema, or heart
disease, then evidence that the plaintiff was genetically predisposed to such a disorder
also would seem to be admissible. From the defendant's standpoint, the only issue is how
to obtain access to such genetic information. The main ways include discovery of existing
medical records, questioning the plaintiff at deposition, compelling a medical
examination of the plaintiff, and questioning the plaintiff's physicians by interrogatories
or depositions.
Although virtually all of the cases involve the defendant's attempt to introduce
evidence of the plaintiff's shorter life expectancy, it is also possible for the plaintiff to
introduce evidence of longevity. For example, in Escobar v. Seatrain Lines, Inc.," a
wrongful death action was brought by the widow of a longshore worker who was killed
while unloading containers on the defendant's ship. In determining lost future earnings,
the jury awarded damages above the work expectancy of the average worker. The court
upheld the verdict.
The jury's calculations obviously were predicated on their finding that at the time
of the accident decedent was in excellent health and had extraordinary prospects for
longevity. An autopsy disclosed that his arteries were free of atherosclerosis and that
his cardio-vascular condition was comparable to that of a 20 year old. His subcutaneous
fat was one fifth of normal, another factor contributing to longevity. Dr. Michael Baden
... testified that decedent would be grouped within the top 5% of persons his age in
terms of life expectancy. His father died at age 89 and his mother was still alive at age
86. Dr. Lawrence Bress ... testified that based on genetic inheritance, decedent's
cardiovascular condition, heart, liver and organs in excellent condition, he could be
expected to outlive his parents."
With genetic prediction becoming increasingly sophisticated, it may be possible to
estimate increased longevity. Nevertheless, for the foreseeable future, it is likely that
decreased life expectancy will be the primary focus in personal injury litigation.
74. Ward v. Loomis Bros., 532 N.W.2d 807, 810-11 (Iowa Ct. App. 1995) (admitting evidence of marijuana use).
Contra Krueger v. General Motors Corp., 783 P.2d 1340, 1346 (Mont. 1989) (excluding evidence of habitual drug use
because it was highly prejudicial).
75. Smith v. Southland Corp., 738 F. Supp. 923,926 (E.D. Pa. 1990); Oxford v. Hamilton, 763 S.W.2d 83, 85 (Ark.
1989); Johnston v. Conger, 854 S.W.2d 480, 484 (Mo. Ct. App. 1993); Jaramillo v. Fisher Controls Co., 698 P.2d 887,
896 (N.M. Ct. App.), cer. denied, 698 P.2d 886 (N.M. 1985). ContraMcCarty v. Gappelberg, 273 S.W.2d 943, 947 (rex.
Civ. App. 1954) (holding evidence of alcohol abuse too prejudicial and its effect on earnings too speculative to allow
admission).
76. Wehmeier v. UNR Indus., Inc., 572 N.E.2d 320, 339-40 (111. App. Ct. 1991); Betts v. Manville Personal Injury
Settlement Trust, 588 N.E.2d 1193, 1223 (11. App. Ct.), appeal denied, 602 N.E.2d 447 (I1. 1992).
77.566 N.Y.S.2d 813 (Sup. CL 1990), rev'd and remanded, 573 N.Y.S.2d 498 (App. Div. 1991) (Escobarfl). The
case was reversed because thejury award was too high. The plaintiff had equated his earning potential with that of a more
qualified employee. The court did not address the issue of life expectancy evidence. Escobar I1, 573 N.Y.S.2d at 500-01.
78. Escobar, 566 N.Y.S.2d at 815; see also Ewing v. Esterholt, 684 P.2d 1053, 1060 (Mont. 1984) (discussing
evidence plaintiff presented regarding longevity).
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Predicting life expectancy and work expectancy are relevant to the issue of estimating
damages. The method by which damages are paid is a separate but related issue.79 The
single recovery or lump sum payment rule provides that the plaintiff s judgment is for all
harms-past and future-caused by the defendant's conduct related to the cause of action.
The plaintiff receives a single award, reduced to present value, that cannot be decreased
or increased even if the plaintiff's situation changes.10
One aspect of the lump sum rule involves awarding damages for future losses.
Obviously, it is speculative to estimate lost life expectancy or lost work expectancy. In
any individual case, the plaintiff's actual life span may be longer or shorter than that
predicted in mortality tables.
No finder of fact can predict whether any specific [individual] will live to the exact time
of the actuarial expectancy, or less, or longer. For if there were such omniscience,
insurance companies would use the omniscient individual to set insurance premiums on
specific individuals rather than relying on actuarial tables.'
Thus, in any individual case, the plaintiff or the defendant may receive a windfall or a
shortfall."
Despite this drawback, there are two main reasons why the lump sum rule has endured
for centuries. First, even though it may result in unfairness in individual cases, it is fair
in the aggregate. Over time, using mortality tables will result in all plaintiffs recovering
the total amount reasonably to be paid by all defendants. Second, it is efficient because
a single recovery is determined in a single proceeding. 3
III. DISCOVERY OF MEDICAL RECORDS
The easiest way for a personal injury defendant to learn a plaintiffs prior medical
history is to discover the plaintiff s medical records. Requests for the medical records of
personal injury plaintiffs are considered routine and are rarely challenged.
Courts considering the issue of discovering a plaintiff s medical records have applied
the general principle that discovery requests are liberally granted."' In general, parties
may discover any nonprivileged matter relevant to a claim or defense of any party to a
lawsuit."5 If evidence of a plaintiff's preinjury health status is admissible on the issue of
79. The doctrines of res judicata and merger also deserve mention. Res judicata is deeply ingrained in Anglo-
American tradition. It traces its origins to Roman law. Essentially, "every person is entitled to his or her day in court...
[b]ut when a final decision has been reached, that should be the end of it" MILTON D. GREEN, BASIC CIVIL PROCEDURE
227 (2d ed. 1979). The two primary purposes of the doctrine are to promote the defendant's interest in not being vexed
twice by the same claim and the public interest of resolving litigation. JACK H. FRIEDENTHAL Er AL., CIvIL PROCEDURE
§ 14.3 (2d ed. 1993).
The second principle to consider, the merger doctrine, provides that once ajudgment for the plaintiff has been reached
in any matter, the cause of action is extinguished and merged into thejudgment. GREEN, supra, at 228. Furthermore, thejudgment ends litigation "as to every ground of recovery or defence actually presented in the action, but also as to every
ground which might have been presented .... Cromwell v. County of Sac, 94 U.S. 351, 353 (1876).
80. See generally Roger C. Henderson, Designing a Responsible Periodic-Payment Systenifor Tort Awards, 32 ARIZ.
L. REy. 21 (1990) (discussing history of lump-sum payment role and alternative forms of periodic payment).
81. Dugas v. National Aircraft Corp., 340 F. Supp. 324, 328 (E.D. Pa. 1972).
82. While the terms "windfall" and "shortfall" may be appropriate in describing the effect on defendants, the plaintiff
receives a windfall only by dying sooner than expected and a shortfall by living longer than expected.
83. For a discussion of the concept of periodic payment of damages, see infra part VI.D.
84. Hickman v. Taylor, 329 U.S. 495, 507 (1947).
85. Rule 26(b)(1) of the Federal Rules of Civil Procedure provides in pertinent part:
Parties may obtain discovery regarding any matter, not privileged, which is relevant to the subject matter involved
in the pending action, whether it relates to the claim or defense of the party seeking discovery or to the claim or
defense of any other party .... The information sought need not be admissible at the trial if the information sought
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damages, 6 then medical records indicating health status are presumptively discoverable.
Thus, courts routinely order the discovery of medical records, 7 including records relevant
to the issue of damages for lost future earnings." Even sensitive information, such as
psychiatric records, have been ordered disclosed. 9
Agosto v. Trusswal Systems Corp." is a particularly illustrative case. In a products
liability action, the defendant sought to discover the plaintiff's medical records and to
depose the plaintiff about his medical history. The defendant apparently had learned that
the plaintiff had tested positive for HIV. After applying a balancing test, the court
ordered discovery.
If [the Defendant] is held liable, damages for these claims will be awarded in part based
on evidence of Plaintiff's life expectancy. It is not certain how many of those who test
positive for the HIV virus contract AIDS, however, AIDS results from HIV infection
and those who contract AIDS have a significantly diminished life expectancy.
Therefore, HIV-related evidence of Plaintiff's health is necessary if [the Defendant] is
to adequately prepare defenses to Plaintiff's claims."
The court did not address the issue of whether the plaintiff's medical records would have
been discoverable in the absence of some well-founded belief on the defendant's part that
the plaintiff was HIV-positive.'2
Another important issue -in the Agosto case involved the effect, if any, of a
Pennsylvania law providing for the confidentiality of HIV-related information. 3 The
court held that by filing the lawsuit the plaintiff had waived his rights under the statute,
and even if he did not waive his rights, the defendant established a "compelling need" for
disclosure under the statute." The plaintiff's only option to resist discovery of his
medical records was to abandon his claim for future damages." "[The Defendant] is
entitled to access to the HIV-related information in this case if Plaintiff decides to
continue pressing his future pain and suffering and lost earning capacity claims.""
Although Agosto involved a specific HIV confidentiality statute, most waiver cases
involve waiver of the physician-patient privilege. The issue of waiver is also important
in light of the existence of various other privilege or confidentiality statutes and the
possibility that other such laws may be enacted.97 For example, some physician-patient
appears reasonably calculated to lead to the discovery of admissible evidence.
FED. R. Civ. P. 26(bX1).
86. See supra part II.
87. See. e.g., O'Boyle v. Jensen, 150 F.R.D. 519, 523-24 (M.D. Pa. 1993).
88. See. e.g., Conrad v. Park, 612 N.Y.S.2d 524, 525 (App. Div. 1994); Hostler v. Tonawanda Super Duper. Inc.,
480 N.Y.S.2d 654, 654 (App. Div. 1984).
89. See. e.g., Tramm v. Porter Memorial Hosp., 128 F.R.D. 666, 667-69 (N.D. Ind. 1989); Evans v. Club
Mediteranee, S.A., 585 N.Y.S.2d 33, 33 (App. Div. 1992).
90. 142 F.R.D. 118 (E.D. Pa. 1992).
91. Id. at 120.
92. For a discussion ofwhen a medical examination, including HIV or genetic testing, may be ordered, see infra part
IV.
93. Pennsylvania Confidentiality of HIV-Rlated Information Act, PA. STAT. ANN., tit. 35, §§ 7601-7612 (1993 &
Supp. 1995).
94. Agosto, 142 F.R.D. at 120.
95. Id.
96. Id. See generally Ugo Colella, HI-Related Informatlion and the Tension 8etween Confidentiality andLiberal
Discovery, 16 J. LEGAL MED. 33 (1995) (suggesting specific criteria for determining whether HIV-related information
should be discoverable in civil disputes).
97. For a further discussion, see infra part VI.C.
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privilege statutes specifically provide that the filing of a lawsuit for personal injury
constitutes a waiver of the statutory privilege.'
There are also three judicial theories applied by the courts in waiver cases. The
simplest is the "automatic waiver rule," which provides that merely by filing the lawsuit
the plaintiff waives all privileges regarding medical record privacy." The second test
balances the compelling need for discovery against the right of privacy." The third
approach uses a three-part test, which focuses on: (a) whether the party asserting the
privilege has initiated the legal action, (b) whether the asserting party has placed the issue
"in controversy," and (c) whether the information is "vital" to the opposing party.' All
three approaches have been subject to criticism, but the effect of these rules-that is,
finding a waiver-is virtually the same under any of the approaches. 2
IV. COMPELLED MEDICAL EXAMINATIONS
The most intrusive form of medical discovery is the compelled medical examination.
Rule 35 of the Federal Rules of Civil Procedure provides that a mental or physical
examination may be ordered by the court in an action in which the mental or physical
condition of a party is "in controversy," upon a showing of "good cause."" 3 The rules of
civil procedure of every state,1"" except Mississippi,"~s contain similar provisions.
In Schlagenhaufv. Holder,"' the Supreme Court considered the meaning of the terms
"in controversy" and "good cause."
98. See. e.g., 42 PA. CONS. STAT. ANN. § 5929 (1982 & Supp. 1995) ("No physician shall be allowed. .. to disclose
any information ... without consent of said patient, except in civil matters brought by such patient, for damages on
account of personal injuries."). The provision applies to any personal injury action and not merely to an action for
malpractice brought against the physician. See Miller v. Colonial Refrigerated Transp., Inc., 81 F.R.D. 741, 743 (M.D.
Pa. 1979); Moses v. McWilliams, 549 A.2d 950, 955 (Pa. Super. Ct. 1988), appeal denied, 558 A.2d 532 (Pa. 1989).
99. See Independent Prods. Corp. v. Loew's, Inc., 22 F.R.D. 266, 276-77 (S.D.N.Y. 1958).
100. The California courts have applied the following balancing test: "Even when discovery of private information
is found directly relevant to the issues of ongoing litigation, it will not be automatically allowed; there must be a careful
balancing of the compelling public need for discovery against the fundamental right of privacy." Estate of Gallio v.
Conigliaro, 39 Cal. Rptr. 2d 470,473 (Ct. App. 1995). The "fundamental right of privacy" in California is based on the
state constitution. See Lantzv. Superior Court, 34 Cal. Rptr. 2d 358, 367 (Ct. App. 1994); Davis v. Superior Court, 9 Cal.
Rptr. 2d 331,335 (Ct. App. 1992). For a different formulation of a balancing test, see Black Panther Party v. Smith, 661
F.2d 1243,1266-67 (D.C. Cir. 1981), vacated without opinion, 458 U.S. 1118 (1982).
101. Hear v. Rhay, 68 F.R.D. 574, 581 (ED, Wash. 1975). In Federal Deposit Ins, Co. v. Wise, 139 F.R.D. 168, 171(D. Colo. 1991), the court restated the Heami test as follows:
If(i) assertion of the privilege is the result of some affirmative act, such as filing suit, by the asserting
party, (ii) through the affirmative action, the asserting party has placed the protected information at issue
by making it relevant to the case, and (iii) application of the privilege would deny the opposing party
access to information vital to its defense, the court should find that the asserting party has impliedly
waived the privilege through its own affirmative conduct.
102. Remington Arms Co. v. Liberty Mut. Ins. Co., 142 F.R.D. 408, 413 (D. Del. 1992). But cf. In re New York
County DES Litig., 570 N.Y.S.2d 804, 805 (App. Div. 1991) (holding that waivers do not extend to the medical histories
of relatives).
103. FED. R. Civ. P. 35(a).
104. State provisions for medical examinations actually preceded the adoption of the Federal Rules of Civil Procedure
in 1938. 8A CHARLEs A. WRIGHT & ARTHUR R. MILLER, FEDERAL PRACnCE AND PROCEDURE § 2231 (1994).
Subsequent to the adoption of the Federal Rules, most states have amended their requirements to conform to the Federal
Rules. There are a few notable exceptions. South Carolina only permits examinations when the amount in controversy is
over $100,000. S.C. R. CIV. P. 35. Florida and Illinois no longer require a showing of good cause. FLA. R. Civ. P. 1.360;
ILL. SUP. CT. R. 215. In California, any defendant may demand one physical examination of the plaintiff at any time
without a showing of"in controversy" or "good cause," so long as the examination is within 75 miles of the plaintiff's
residence and the examination does not include any diagnostic test that is painful, protracted, or intrusive. CAL. CiV. PROC.
CODE § 2032 (West 1996).
105. Miss. R. Civ. P. 35; Swan v. I.P., Inc., 613 So. 2d 846, 859 (Miss. 1993).
106. 379 U.S. 104 (1964).
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[These requirements] are not met by mere conclusory allegations of the pleadings-nor
by mere relevance to the case-but require an affirmative showing by the movant that
each condition as to which the examination is sought is really and genuinely in
controversy and that good cause exists for ordering each particular examination.
Obviously, what may be good cause for one examination may not be so for another. The
ability of the movant to obtain the desired information by other means is also
relevant."o7
Schlagenhauf has been interpreted by both federal"0 and state' °9 courts to mean that
any time a plaintiff seeks to recover for physical injuries, his or her physical condition
is "in controversy." Although this may establish the discoverability of plaintiff's medical
records pursuant to Rule 26,110 it does not necessarily establish the existence of good
cause for a medical examination. An important question is whether information in the
plaintiff's medical records can establish good cause for a medical examination. This is
crucial to the issue of genetics, because information in the plaintiff's medical record may
cause the defendant to suspect an underlying genetic condition, and then seek to have a
court-ordered medical examination that includes genetic testing.
In Pettyjohn v. Goodyear Tire & Rubber Co., ' the plaintiff brought a products
liability action in which he sought to recover damages for personal injuries caused by the
explosion of a tire. In the course of reviewing the plaintiff's medical records, the
defendant observed a notation in the margin of one report indicating that the plaintiff was
HIV-positive. The defendant, in attempting to limit its damages for future earnings, then
sought an order requiring that plaintiff submit to a blood test. The district court held that
the plaintiff s HIV status was in controversy and required the plaintiff to undergo HIV
testing or forgo any claims for future damages."' Likewise, in other cases, good cause to
107. Id. at 118.
108. See. e.g., Vopelak v. Williams, 42 F.R.D. 387, 389 (N.D. Ohio 1967).
109. See, e.g., May v. Lawrence, 751 S.W.2d 678, 679 (rex. Ct. App. 1988).
110. See supra part III.
111. Civ. A. No. 91-CV-2681, 1992 Wi. 105162 (ED. Pa. Apr. 29, 1992).
112. For a discussion of the case, see Peter H. Berge, SettingLimits on Involuntary HIVAntibody Testing Under Rule
35 and State Independent Medical Examination Statutes, 44 FLA. L. REV. 767 (1992). in Sacramona v.
Bridgestone/Firestone, Inc., 152 F.R.D. 428, 432 (D. Mass. 1993), a United States magistrate judge refused to follow
Pettyjohn.
Forty-three states have statutes that deal with compelled HIV testing, although most of these laws would permit court-
ordered testing pursuant to a discovery order. See ALA. CODE § 22-1 IA-51 (Supp. 1995); ARIz. REV. STAT. ANN. § 36-
663(a) (Supp. 1995); ARK. CoDEANN. § 20-15-905 (Michie 1991); COLO. REV. STAT. ANN. § 25-4-1401 (West 1990 &
Supp. 1995); CONN. GEN. STAT. ANN. § 19a-582 (West Supp. 1995); DEL. COnE ANN. tit. 16, § 1202 (Supp. 1995); FLA.
STAT. ANN. § 381.004(3Xa) (West 1993); GA. CODE ANN. §§ 31-17A-2 to -3 (1991); HAW. REV. STAT. § 325-16 (1993);
IDAHO CODE § 39-610 (1993); ILL. ANN. STAT. ch. 410, para. 305/4 to 305/9 (Smith-Hurd 1993 & Supp. 1995); IND.
CODE § 16-41-6-1 (1993); IOWA CODEANN. § 141.22 (West 1989 & Supp. 1995); KAN. STAT. ANN. § 22-2913(c) (1988
& Supp. 1994); KY. REv. STAT. ANN. §§ 214.181(5)(a), 214.625(5)(a) (Michie/Bobbs-Merrill 1995); LA. REV. STAT. ANN.
§ 40:1300.13.A (West 1992 & Supp. 1995); ME. REV. STAT. ANN. tit. 5, § 19203-A (West 1989 & Supp. 1995); MD.
HEALTH-GEN. CODE ANN. §§ 18-336, 18-338.1(b), (c) (1994 & Supp. 1995); MASS. GEN. LAWS ANN. ch. 111, § 70F
(West 1995); MINcH. CM,. LAws § 333.5133(2) (1991); MINN. STAT. ANN. § 144.765 (West Supp. 1996); MISS. CODE
ANN. § 41-41-16 (1993); Mo. ANN. STAT. § 191.674 (Vernon Supp. 1996); MONT. CODE ANN. § 50-16-1007(1) (1995);
N.H. REV. STAT. ANN. § 141-F:5 (1990 & Supp. 1995); N.M. STAT. ANN. § 24-21-2 (Michie 1994); N.Y. PUB. HEALTH
LAW § 2781.1 (McKinney 1993 & Supp. 1996); N.C. GEN. STAT. § 130A-148(h) (1995); N.D. CENT. CODE § 23-07.5-02
(1991 & Supp. 1995); OIO REV. CODEANN. § 3701.242(A) (Anderson 1995); OKLA. STAT. ANN. tit. 63, § 1-502.3 (West
Supp. 1996); OP. REV. STAT. § 433.045 (1992); PA. STAT. ANN. tit. 35, § 7605 (1993); R.I. GEN. LAWs §§ 23-6-12 to -14
(1989 & Supp. 1995); S.C. CODEANN. §§ 16-15-255,44-29-230 (Law. Co-op. Supp. 1995); S.D. CODIIED LAWS ANN.
§ 23A-35B-3 (Supp. 1995); TENN. CODE ANN. § 39-13-521 (Supp. 1995); TEX. HEALTH & SAFETY CODE ANN. § 81.105
(West 1992); UTAH CODE ANN. § 64-13-36 (1993 & Supp. 1995); VA. CODEANN. § 32.1-37.2(A) (Michie 1992); WASH.
REV. CODE ANN. § 70.24.330 (West 1992); W. VA. CODE § 16-3C-2(c) (1995); Wis. STAT. ANN. § 146.025(2) (West
1989).
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order a mental examination was established by the ambiguity of the plaintiff's medical
records" 3 and statements of the plaintiffs physician."
4
Even when the "in controversy" and "good cause" requirements of Rule 35 are
satisfied, the court has discretion in deciding whether to compel an examination." 5 In
general, the cases in which courts order a physical or mental examination fall into three
categories.
First, the information must not be available elsewhere. The movant must show that
other discovery procedures, such as the production of medical records, have been
exhausted." 6 Second, it must be established that useful information is likely to be gained
from the examination. For example, repetitive examinations will not be permitted" 7
unless special circumstances justify an additional examination."" Third, the examination
must not create health risks to the examinee. Although most of the cases involving health
risks are concerned with physical risks," 9 there is some support for the view that the
feelings, reputation, and psychological impact on the examinee also should be
considered. 20 For example, in Doe v. Roe,'2' maternal grandparents attempted to gain
custody of their grandchild from the allegedly unfit father. They sought an order
requiring the child's father to have an HIV test. In rejecting the motion, the court noted
that "the psychological impact of learning that one is [HIV-positive] has been compared
to receiving a death sentence."'
22
The potential psychological and social harm to the examinee is merely one factor to
consider in the context of genetics. Public policy concerns about confidentiality and
conservation of resources, discussed in the next section, also need to be weighed against
the need for the information revealed by the testing. These issues are likely to arise in
motions to compel genetic testing under Rule 35 .11 The few cases that have been decided
under this rule, however, have not developed the issues sufficiently to provide needed
guidance to courts dealing with a genetics case of first impression.
113. Everly v. United Parcel Serv., Inc., No. 89-CV-1712, 1991 WL 18429 (N.D. III. Feb. 5, 1991).
114. Hodges v. Keane, 145 F.R.D. 332,335 (S.D.N.Y. 1993). The evidence from the examination was later excluded
from trial because it was too prejudicial. Hodges v. Keane, 886 F. Supp. 352 (S.D.N.Y. 1995).
115. Stinchcomb v. United States, 132 F.R.D. 29, 30 (E.D. Pa. 1990) (citing Hardy v. Riser, 309 F. Supp. 1234, 1241
(N.D. Miss. 1970)).
116. Marroni v. Matey, 82 F.R.D. 371,372 (E.D. Pa. 1979).
117. See Loveland v. Kremer, 464 N.W.2d 306, 309 (Minn. Ct. App. 1990).
118. Special circumstances include the need for examination by separate specialists, Marshall v. Peters, 31 F.R.D.
238,239 (S.D. Ohio 1962); additional consultation, Little v. Howey, 32 F.R.D. 322 (W.D. Mo. 1963); completion of the
first examination, Mayer v. Illinois N. Ry., 324 F.2d 154, 156 (7th Cir. 1963), cert. denied, 377 U.S. 907 (1964); or
updating results of a prior examination, see Vopelak v. Williams, 42 F.R.D. 387, 389 (N.D. Ohio 1967). See generally
Moore v. Calavar Corp., 142 F.R.D. 134 (W.D. La. 1992) (providing overview of circumstances under which a second
examination isjustified).
119. Simple medical procedures will be ordered. See Beach v. Beach, 114 F.2d 479, 482 (D.C. Cir. 1940) (blood test
ordered); Mirabile v. Profy, 522 N.Y.S.2d 197, 198 (App. Div. 1987) (x-rays ordered). The courts are less clear about more
complicated procedures. Compare Hernandezv. Gulf Oil Corp., 21 Fed. R. Serv. 2d (Callaghan) 1378, 1378 (E.D. Pa.
1976) (bone scan not ordered); Riss & Co. v. Galloway, 114 P.2d 550, 551-52 (Colo. 1941) (spinal puncture not ordered)
and O'Brien v. City of La Crosse, 75 N.W. 81, 81 (Wis. 1898) (catheterization of bladder not ordered) with Klein v.
Yellow Cab Co., 7 F.R.D. 169, 170 (N.D. Ohio 1945) (eystoscopic examination ordered) andCardinal v. University of
Rochester, 71 N.Y.S.2d 617, 618 (Sup. Ct. 1947) (bone marrow biopsy ordered).
120. Hardy v. Riser, 309 F. Supp. 1234, 1241 (N.D. Miss. 1970) (dictum).
121. 526 N.Y.S.2d 718 (Sup. Ct. 1988).
122. Id. at 722. Where the potential harm to the party seeking discovery is physical, the courts are more likely to order
discovery despite claims of confidentiality. See Syring v. Tucker, 498 N.W.2d 370, 377-78 (Wis.) (ordering HIV testing
in case in which defendant, who intentionally bit the plaintiff, claimed to be HIV-positive), reconsideration denied, 505
N.W.2d 142 (Wis. 1993).
123. For a further discussion, see infra part VI.C.
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V. PUBLIC POLICY ISSUES
Parts I through IV of this Article have discussed the new developments in genetics and
how, under the current law of damages and civil procedure, genetic information might
be relevant and discoverable. The key question is whether permitting personal injury
defendants to gain access to individual genetic profiles through medical records or
compelled genetic testing is good public policy.
This Part begins by drawing two important distinctions: (1) the difference between
medical and nonmedical uses of genetic information, and (2) the difference between
genetic and other forms of medical information. After concluding that the nonmedical use
of genetic information raises special concerns and that genetic information is a special
form of information, the ethical principles of privacy, autonomy, confidentiality, and
nonmaleficence are applied to the use of genetic information in personal injury litigation.
A. Medical vs. Nonmedical Uses of Genetic Information
A variety of extremely important and complex policy issues revolve around the broad
issue of using genetic information for medical purposes. These include informed consent,
the duty to warn, public health screening, and medical malpractice.'24 The seeming
immediacy of these concerns sometimes has obscured the equally important, and in some
ways more troublesome, potential for nonmedical or secondary use of genetic
information. The power of genetic information gives rise to the likelihood that
individuals and entities with a financial, personal, or similar interest in identifying an
individual or predicting an individual's future health or behavior will seek to obtain and
use this information. 1
25
The broad range of potential uses of genetic information makes it extremely
venturesome to formulate ethical, legal, or social principles of universal applicability.
Certain themes, however, recur. They involve resolving the conflicts between individuals
and third parties over control of individual genetic information; balancing the potential
benefits of certain genetic information against the costs and consequences of obtaining
it; and placing into proper perspective the enormous evolutionary, psychological, and
social power of genetic information.
In its 1994 report entitled Assessing Genetic Risks: Implications for Health and Social
Policy, a committee of the Institute of Medicine of the National Academy of Sciences
124. As developed by the Ethical, Legal, and Social Implications Program of the National Center for Human Genome
Research, these include the following issues: (1) priorities, strategies, and protocols in research; (2) intellectual property,
corporate-governmental relations, and other issues in commercial applications; (3) clinical guidelines on when it is
appropriate to offer genetic testing; (4) genetic counseling of at-risk individuals, affected individuals, and their families;
(5) confidentiality of medical records containing genetic information and the duty to warn relatives of affected individuals;
(6) professional and public education; (7) public health strategies to prevent, diagnose, and treat genetic diseases; (8)
access to genetic services, including prenatal testing; (9) genetic services as a part of health care resource allocation; and(10) reimbursement issues. See PROGRESS REPORT, supra note 3, at 40-47.
125. Among the possible secondary uses of genetic information ar the following: (I) identifying biological specimens
or remains; (2) assessing capacity for employment; (3) underwriting health, life, and disability insurance; (4) assessing
risk in mortgages and other commercial transactions; (5) applying identification or future health considerations to domestic
relations, including paternity, child custody, and adoption; (6) selecting and testing of students in primary, secondary, and
higher education; (7) determining mental capacity or potential for recidivism in the criminal justice system; and (8)
establishing causation and damages in tort litigation. See Mark A. Rothstein, The Use of Genetic Information for
Nonmedical Purposes, 9 J.L. &HEALTH 109, 110-18 (1994-95).
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reaffirmed the principle that genetic tests "should be of benefit to the individual being
tested."' 1 The committee expressed concern about the nonmedical use of genetic
information, and said it was "concerned that some uses of genetic test information may
represent harmful and unwarranted intrusions on individual privacy."
127
The previous statement suggests that genetic information may be different from other
types of medical information and that compelled disclosure of genetic information may
constitute an invasion of privacy. These two themes are addressed below. In a more
general sense, however, the statement raises the issue of nonmaleficence, the bioethics
principle that harm ought not be inflicted intentionally in the provision of medical
services.'2 This principle is not absolute, especially when the harms are not physical but
are social or psychological. Yet the magnitude of the potential negative consequences of
genetic testing is great.'2 9 Therefore, when a social good, such as getting a job or
recovering in tort for personal injury, is conditioned on disclosing genetic records or
submitting to genetic testing, there should be a compelling need for the information
derived from the test. As described more fully below, the use of genetic testing for
discovery of future damages would not meet this test. 3
B. Genetic vs. Other Medical Information
An initial focus of the Human Genome Project has been to identify the genes
responsible for many of the most widespread or lethal single-gene disorders. Even with
this group of disorders, but especially after the focus expanded to include multifactorial
disorders, it became increasingly clear that environmental factors are extremely important
to the course of "genetic" diseases. At the same time, new studies have demonstrated that
many common, seemingly "nongenetic" disorders, from familial hypercholesterolemia 3
and hypertension32 to osteoporosis,'3 have demonstrable genetic components. It is
indisputable that the lines are blurred between genetic and nongenetic disorders and,
indeed, it may become more widely recognized in the scientific world that it is
inadvisable to perpetuate the distinction. 34
Given the current scientific thinking, is there any reason why genetic information
should be subject to greater protection than other kinds of medical information? There
are three reasons, all of which are more social than medical.
First, there is a seeming inevitability to genetic disorders, even at the presymptomatic
stage, that is rare for "nongenetic disorders."' Notwithstanding variable penetrance,
126. ASSESSING GENETIC RISKS, supra note 42, at 47.
127. Id.
128. See TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS 189 (4th ed. 1994).
129. For a further discussion of nonmaleficence, see infra part V.C.3.
130. In other instances in which there is a compelling need to test, all appropriate steps should be taken to minimize
the psychological and social harm caused by the genetic information. This would include confidentiality protections and,
where individual diagnostic information is revealed, appropriate genetic counseling.
13 1. Joseph L. Goldstein et al., Familial Hypercholesterolemia, in 2 THE METABOLIC AND MOLECULAR BASES OF
INHERITED DISEASE 1981 (Charles R. Scriver et al. eds., 7th ed. 1995).
132. See Wylie Burke & Amo G. Motulsky, Hypertension, in THE GENETIC BASIS OF COMMON DISEASES, supra note
25, at 170.
133. Nigel A. Morrison et al., Prediction of Bone Densilyfrom Vitamin D ReceptorAlleles, 367 NATURE 284 (1994).
134. See Philip J. Boyle, Shaping Priorities in Genetic Medicine, HASTINGS CTR. REP., May-June 1995, at S2, S4.
135. A notable exception is HIV infection. The inevitability of symptoms of HIV disease in the future (along with the
lethality of the condition and the stigma associated with the mode of transmission and the makeup of the affected groups)
contribute to the psychological and social burdens of asymptomatic HIV infection.
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variable expressivity, and other scientific principles discussed earlier, 36 at least as to late-
onset monogenic disorders, being presymptomatic means there is a high likelihood of
being affected in the future. Moreover, individuals are often regarded as helpless to
prevent genetic disorders.
Second, a great stigma attaches to genetic disorders, and that stigma directly relates to
the fact of heritability. 37 Genetic disorders run in families; parents, siblings, and other
relatives may be affected or at risk. The risk of transmission to offspring also may create
a barrier to reproduction.33 The transgenerational aspect of genetic disease makes it
especially odious, because it may be viewed as a flaw in one's ancestors and a cloud
hanging over future progeny for generations to come.'
Third, some genetic traits naturally fall along racial and ethnic lines.'40 The abominable
misuse of genetic information for eugenic purposes in the 20th century in the United
States, not to mention Nazi Germany, is alone enough to give great pause to any
unrestrained discovery of genetic information or compelled genetic testing.'4'
All three of these reasons reinforce the notion that it is not the genetic etiology of the
disorders, but the reaction of other people, including family members and third parties,
that causes the deleterious social consequences. Nevertheless, in light of the factors just
mentioned, the reluctance of individuals to divulge genetic information is not irrational
and cannot be overlooked in developing policies to prevent individuals from suffering
the stigma and discrimination associated with genetic disorders.
C. Ethical Issues in Discovery of Genetic Information
1. Privacy/Autonomy
Privacy involves a condition of limited access to a person.' As a legal concept, the
right to privacy is the right of a person to be left alone, to have some element of his or her
person free from intrusion by others. 43 According to one view, privacy has three major
usages: physical privacy ("freedom from contact with other people"); informational
privacy (freedom from "accessibility of personal information"); and decisional privacy
(freedom to make "autonomous choices about the personal and intimate matters that
constitute private lives")."44
136. See supra notes 43-53 and accompanying text.
137. See Howard Markel, The Stigma of Disease: Implications of Genetic Screening, 93 AM. J. MED. 209 (1992).
138. Cf James Sorenson, What We Still Don't Know About Genetic Screening and Counseling, in GENE MAPPING:
USING LAW AND ETHICS AS GUIDES 203 (George J. Annas & Sherman Elias eds., 1992). See generally WOMEN AND
PRENATAL TESTING: FACING THE CHALLENGES OF GENETIC TECHNOLOGY (Karen H. Rothenberg & Elizabeth J.
Thomson cds., 1994).
139. See generally BARBARA KATZ ROTHMAN, THE TENTATIVE PREGNANCY: PRENATAL DIAGNOSIS AND THE
FUTURE OF MOTHERHOOD (1986).
140. Patricia A. King, The Past as Prologue: Race. Class & Gene Discrimination. in GENE MAPPING: USING LAW
AND ETHICS AS GUIDES, supra note 138, at 94; see ANTHONY P. POLEDNAK, RACIAL AND ETHNIC DIFFERENCES IN
DISEASE (1989); see also TROY DUSTER, BACKDOORTO EUGENICS (1990).
141. See generally DANIELJ. KEVLES, IN TIlE NAME OF EUGENICS: GENEICS AND THE USES OF HUMAN HEREDITY
(1985); 1. DAVID SMITH, THE EUGENIC ASSAULT ON AMERICA (1993).
142. See Ruth Gavison, Privacy and the Limits of Law, 89 YALE L.J. 421 (1980).
143. See Samuel D. Warren & Louis D. Brandeis, The Right to Privacy, 4 HARV. L. REV. 193 (1890); see also William
J. Winslade & Judith Wilson Ross, Privacy. Confidentiality, andAutonomy in Psychotherapy, 64 NEB. L. REV. 578 (1985).
144. Anita L. Allen, Privacy in Health Care, in 4 ENCYCLOPEDIA OF BIOETHICS 2064, 2064-65 (Warren T. Reich
ed., 1995).
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All three usages of privacy could be implicated in the discovery of a personal injury
plaintiff's genetic profile. If genetic testing were ordered by a court, there would be an
incursion on physical privacy. The information revealed by the test or through discovery
of extant genetic medical records would be an intrusion on informational privacy. The
compelled submission to testing, which would reveal this information, would constrain
decisional privacy.
All three usages, but especially decisional privacy, relate closely to the concept of.
autonomy. "Rights of privacy are valid claims against unauthorized access that have their
basis in the right to authorize or decline access. These rights are justified by rights of
autonomous choice that are correlative to the obligations expressed in the principle of
respect for autonomy."' 45 One aspect of autonomy is self-determination. It may be viewed
as a negative right which "imposes on everyone the obligation not to coerce or otherwise
interfere with the action of another."'46 Furthermore, "[iln the context of genetic testing
and screening, respect for autonomy refers to the right of persons to make an informed,
independentjudgment about whether they wish to be tested and then whether they wish
to know the details of the outcome of the testing."'47
Autonomy and informed consent are the cornerstones of nondirective genetic
counseling. "Concern about early abuses in the eugenics movement helped to make the
principle of nondirectiveness, and the corollary of respect for client autonomy, key
concepts of genetic counseling today.""' This is especially important in respecting the
wishes of clients about whether to undergo genetic testing to learn their risk of late-onset
genetic disorders.
Huntington's disease ("HD") is an example of a disorder that often places at-risk
individuals in a quandary. Before the discovery of the HD gene, most at-risk individuals
(56% to 77%) said they would take a test if one were available. But when a test actually
was developed, a much lower percentage wanted to be tested. In one study, only 9.5%
wanted to be tested.' The five most important reasons for refusal cited by the
investigators included: "(1) if the results were adverse, the risk of developing HD for
existing children would increase, (2) the absence of an effective cure, (3) potential loss
of health insurance, (4) financial costs of testing, and (5) inability to 'undo' the
knowledge."' 0
The decision whether to undergo genetic testing for a serious late-onset genetic
disorder is extremely difficult.'5' Even with informed consent and nondirective
counseling, the effect of the test result on an individual and the individual's family can
be devastating. In the absence of a compelling reason, one must conclude that a court
order directing an individual to submit to genetic testing to detect late-onset genetic
145. BEAUCHAMP & CHtLREs, supra note 128, at 410.
146. BruceMiller, Autonomy, in I ENCYcLOPEDIA OF BIOETcs, supra note 144, at 215, 217; see also Bruce Miller,
ypesofAutonomy and TheirSignificance, in BioETHIcs: READINGs AND CASES 105-09 (Baruch A. Brody & H. Tristram
Engelhardt, Jr. eds., 1987).
147. AssEsSING GENEriC RISKS, iupra note 42, at 248.
148. Id. at 152.
149. Kimberly A. Quaid & Michael Morris, Reluctance to Undergo Predictive Testing: The Case of Huntington's
Disease, 45 AM. J. MED. GENETICs 41,43 (1993).
150. Id.; see also Sandi Wiggins et al., The Psychological Consequences of Predictive Testing for Huntington 's
Divease, 327 NEW ENG. J. MED. 1401 (1992); Charles Siebert, The DNA We've Been Dealt, N.Y. TIMES, Sept. 17, 1995,
§ 6 (Magazine), at'50.
151. See Nancy Wexler, Clairvoyance and Caution. Repercussionsfrom the Human Genome Project, in THE CODE
OF CODES: SCIENTIFIC AND SOCIAL ISSUES INTHE HUMAN GENOME PROJECT 211 (Daniel J. Kevles & Leroy Hood eds.,
1992).
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disorders violates the ethical principle of nonmaleficence. The genetic testing is not
rendered ethically acceptable merely because it is nominally "voluntary," when refusing
to comply with the testing surrenders a possibly substantial legal claim for compensation
resulting from the wrongful conduct of the defendant. Public policy, therefore, must be
to prohibit such coerced testing.
2. Confidentiality
Although sometimes used interchangeably with privacy, confidentiality refers to an
individual's reasonable expectation that certain sensitive ififormation revealed within a
confidential relationship will not be redisclosed to a third party without the individual's
consent.5 2 Ever since the Oath of Hippocrates in the fifth century B.C., confidentiality
has been "one of the cardinal obligations of physicians.""' Unless patients are assured
that their communications will not be revealed, they will not be forthcoming with
sensitive information, thereby impeding the effectiveness of medical interventions.
In general, medical information is regarded as confidential.' 4 With the exception of
statutory obligations (e.g., reporting gunshot wounds, child abuse, communicable
diseases)'" or common law obligations (e.g., reporting threats to kill identifiable
victims),'56 medical information will not be disclosed without the consent of the patient.
Confidentiality is an instrumental value; its significance depends on the importance of
the underlying values it promotes. In the context of genetic information, the underlying
values, including preventing psychological and social harm to the individual, are
substantial.
Confidentiality has not been accorded great weight in lawsuits. In personal injury
litigation, however, the theory has developed that the plaintiff, by placing his or her
medical condition in issue, has impliedly consented to the disclosure of relevant medical
information to the defendant.'57 Failure of the plaintiff to produce the medical records or
to submit to a court-ordered medical examination is grounds for dismissal.' 5 The
defendant's interest in determining the validity of the plaintiffs claim is deemed to
outweigh the plaintiffs interest in confidentiality.
Two public policy issues stem from the disclosure (including disclosure in the course
of litigation) of confidential genetic information. First, as with all sensitive medical
information, compelled disclosure creates a risk of embarrassment and stigma.5 9 Genetic
information may be considered to touch the essence of humanity. It also reveals
information about the individual's relatives-past, present, and future. In an estimated
152. See William J. Winslade, Confidentiality, in I ENCYCLOPEDIA OF BIOETHICS, supra note 144, at 451, 452.
153. BIOETHICS: READINGS AND CASES, supra note 146, at 291.
154. See Howard Brody, 7he PhysiciatiPalient Relatiothip, in MEDICAL ETHICS 65 (Robert M. Veatch ed., 1989).
But see Robert M. Gellman, Prescribing Privacy: The Uncertain Role of the Physician in the Protection of Patient
Privacy, 62 N.C. L. REV. 255 (1984) (noting the widespread secondary use of medical information).
155. See FRANK P. GRAD, THE PUBLIC HEALTH LAW MANUAL 286 (2d ed. 1990).
156. See Tarasoffv. Regents ofthe Univ. ofCal., 551 P.2d 334 (Cal. 1976) (holding that psychotherapist has common
law duty to warn identifiable, intended victim of patient's death threats).
157. See supra notes 99-102 and accompanying text.
158. See, e.g., Schempp v. Reniker, 809 F.2d 541 (8th Cir. 1987) (psychological examination); Agosto v. Trusswal
Sys. Corp., 143 F.R.D. I I&(E.D. Pa. 1992) (medical records).
159. This assumes that them will not be further redisclosure or use of this information, in which case there would be
secondary risks of discrimination or further embarrassment.
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one to ten percent of births, paternity is misattributed. 60 This information could be
divulged in the course of performing genetic testing of a plaintiff.',' Confidentiality
demands that sensitive information of this nature not be revealed without a compelling
reason.
Second, rules on the confidentiality of medical information have a marked effect on the
willingness of individuals to disclose sensitive information in the clinical setting. In the
context of genetic testing, public policy should encourage at-risk individuals who are so
inclined to undergo genetic testing without fear that their genetic records will be
disclosed without their truly voluntary consent. It is unlikely that individuals would
decline genetic testing because they feared that if they were involved in an accident, their
genetics test results could be discovered in a personal injury case. Nevertheless, the
discovery of medical records in litigation must be considered in the context of other
secondary uses of genetic information. Many individuals who decline testing are
concerned that employers, insurers, or other third parties might gain access to the
information. As with these other third party users, in the absence of a compelling reason,
genetic medical records should be beyond the reach of discovery in personal injury
litigation.
3. Nonmaleficence
The bioethics expression of the principle of nonmaleficence-primum non nocere, or
"above all do no harm"-is well known, although "its origins are obscure and its
implications unclear."'16 The harms to be avoided under nonmaleficence include not only
physical injuries, but also personal, psychological, familial, and social injuries. Thus, the
harms may be intangible as well as tangible, and they may be the consequence of actions
which are not, in themselves, inherently maleficent.
Several potential harms already have been discussed in this section. These include
invasions of privacy and overriding individual autonomy where genetic testing is ordered
over the objection of the individual. Plaintiffs in personal injury actions, it was noted,
could be given the choice of acquiescing in genetic testing, and possibly being confronted
with information that they preferred not to know, or relinquishing their claims to recover
for substantial harms that were inflicted on them by allegedly responsible third parties. 63
If genetic records developed in the clinical setting were discoverable, clients could face
a possible breach of confidentiality in the redisclosure of personal information, and
concerns about later disclosures might dissuade those at-risk individuals who wanted to
be tested.
160. See Sally Macintyre & Anne Sooman, Non-Paternity and Prenatal Genetic Screening, 338 LANCET 869 (1991)
(asserting that the common medical school estimate of 10-15% is too high); see also DJ.H. Brock & A.E. Shrimpton, Non-
Paternity and Prenatal Genetic Screening, 338 LANCE 1151 (1991) (letter to editor) (arguing that figure is closer to one
percent).
16 1. For example, assume that a male plaintiffis tested for a late-onset, recessive disorder, such as Wilson's disease
or hemochromatosis. The test indicates that the individual is homozygous unaffected. This means he does not carry even
a single copy of the aberrant allele. If he has a social child who is presymptomatic homozygous affected for the recessive
disorder, then the male who underwent the testing could not be the biological father of the child.
162. BEAUCHAWP & CHILORESS, supra note 128, at 189 (alterations omitted).
163. It is possible that compelled genetic testing could reveal the presence of a latent genetic condition that the
individual could avoid through behavior modification or medical intervention. Under such circumstances, the genetic
testing might be viewed as beneficial. Nevertheless, these occurrences are likely to be rare and, in any event, incursions
on individual autonomy are not rendered acceptable because the result is considered "positive" by society. After all,
automomy is in part the right of self-determination when the individual disagrees with the prevailing societal view.
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Besides coercion and discouragement, there are three other harms to be avoided.
Avoiding these harms supports the public policy of prohibiting the discovery of genetic
information' and not permitting compelled genetic testing.
First, we ought not permit genetic testing when it is not being used primarily for the
benefit of the person being tested. Overriding considerations of public health and safety
must be met before using such a powerful technology beyond the clinical setting.", The
genetics literature contains numerous reports of psychological harms, including suicide,
involving individuals who were unable to adjust to genetic information.'66
Second, substandard genetic testing and counseling ought to be avoided. An
increasingly costly component of the overall genetic testing process is genetic
counseling. When a court compels genetic testing of a personal injury plaintiff paid for
by the defendant, it is unlikely that time-consuming, nondirective genetic counseling also
will be included. Thus, a possibility exists that individuals will not only be confronted
with potentially devastating information that they did not want to know, but they will
receive little or no counseling before or after the test to prepare them to deal with the
information. Indeed, in genetic counseling it is often suggested that individuals deemed
unprepared to receive possibly difficult information should defer their testing until a
more propitious time. That alternative would not be available in the course of litigation.
Third, genetic resources, human and financial, ought not be wasted. As of 1995, there
were only 792 board-certified clinical geneticists and 814 board-certified genetic
counselors in the United States. 67 With the expense of genetic testing and counseling,
and with a finite number of trained professionals, there already is great concern that
access to appropriate genetic services will not be available to all individuals who want
them. '6
By contrast, each year there are nearly one million tort cases brought in the United
States. 6 9 If genetic information about the plaintiff became an issue in even a small
percentage of these cases, genetic services providers would be overwhelmed. Wealthy,
institutional defendants would syphon off a substantial amount of genetic resources to
perform genetic testing and testify about the results. This is a troubling prospect because
164. For a discussion of laws protecting the confidentiality of'substance abuse treatment records and HIV test results,
see infra parts VI.C.! .a and VI.C.I .b.
165. Some examples of possiblejustifications for genetic testing would be establishing filial relations and conducting
DNA forensics associated with a criminal investigation. The specifics of these exceptions are beyond the scope of this
Article.
166. See, e.g., Lindsay A. Farrer, Suicide andAttempted Suicide in Huntington Disease: Implications'for Preclinical
Teiling of Personv at Risk, 24 AM.J. MED. GENETICS 305,305 (1986) (reporting that 5.7% of HD patients died of suicide
and 27.6% attempted suicide at least once).
167. The American Board of Medical Genetics administers an examination every three years. The most recent
examination was in 1993. The figure of 792 clinical geneticists does not include Ph.D. medical geneticists, clinical
cytogeneticists, clinical biochemical geneticists, and molecular geneticists. The total number of board certifications in all
of these categories is 1686, although some individuals are certified in more than one category. Telephone Interview with
Sharon Robinson, Administrator, American Board of Medical Genetics (Aug. 29, 1995).
168. See ASSESSING GENETIC RisKs, supra note 42, at 20-21; Benjamin S. Wilfond & Norman Fost, The Introduction
of Cystic Fibrosis Carrier Screening into Clinical Practice: Policy Considerations, 70 MILBANK Q. 629 (1992). See
generally THE HUMAN GENOME PROJECT AND ThE FUTURE OF HEALTH CARE (Thomas H. Murray et al. eds., forthcoming
1996).
169. This estimate was derived in the following manner. According to the most recent study by the National Center
for State Courts, in 1993 there were 532,391 tort cases filed in the 27 states studied. BRIAN J. OSTROM & NEAL B.
KAUDER, STATE JUSTICE INSTITUTE, EXAMINING THE WORK OF STATE COURTS 22 (1993). These states had a total
population in 1993 of 172,723,000, approximately 67% of the 1993 population of the United States of 257,783,000.
Therefore, in 1993, all state court filings may be estimated at 798,000. Including the tort cases filed in the federal courts
and projecting population data to 1995 leads to the estimate of nearly one million tort cases filed.
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genetic tests performed for purposes of litigation provide little or no medical benefit
either to the individuals tested or to society.
VI. ALTERNATIVES TO PREVENT DISCOVERY OF GENETIC
RECORDS AND COMPELLED GENETIC TESTING
A. Drawing Lines and Weighing Costs and Benefits
The policy interests discussed in Part V do not mesh well with the current legal rules
on discovery and damages. Indeed, it is a daunting task to devise feasible modifications
to civil procedure and the law of damages to accommodate the substantial policy interests
in protecting genetic information. The outer extremes are easy to describe. It would
violate public policy to permit unfettered access to genetic information and genetic
examinations of personal injury plaintiffs at the whim of defendants. It also would be
unfair to defendants to award compensatory damages for lost future earnings while the
court excludes all evidence of the plaintiffs' preinjury or future health. Thus, it is
necessary to find a middle ground, and this process involves drawing lines, making
distinctions, and balancing interests. This Subpart outlines the appropriate places to begin
drawing these lines.
One starting point is to focus on the reason genetic information is sought. Here, there
is a vital distinction between genetic evidence relevant to the issue of causation and
genetic evidence relevant to the issue of damages. With adequate protective orders
prohibiting redisclosure of the information, evidence of the plaintiffs genetic profile
should be discoverable when it is relevant to the issue of causation.
For example, in a products liability lawsuit filed in 1990, a juvenile plaintiff alleged
that his severe birth defects, including microcephaly and mental retardation (including
an I.Q. of forty), were caused by his in utero exposure to the solvent methyl ethyl ketone
as his mother worked assembling electronics components. 70 The defendant's experts
claimed that the plaintiff s physical and behavioral characteristics suggested the cause
of his injuries was not solvent exposure, but fragile X syndrome, a genetic disorder.,''
The court ordered that medical personnel be allowed to draw two, ten cubic centimeter
blood samples for genetic testing, rejecting the argument that this was an invasive
procedure which would cause severe distress. 72
Before genetic testing is ordered to help establish the cause of plaintiffs' injuries,
courts should require a clear showing of a basis in fact to suspect that the testing is
necessary. Furthermore, a protective order should be issued to limit the disclosure of the
results. As discussed below, because genetic testing should not be ordered merely as a
170. Severson v. Markem Corp., No. 698517 (Super. Ct. Feb. 26, 1990). Fora discussion of this unreported case, see
Sally Lehrman, Pushing Limits of DNA Testing: Suit Prompts Study into Whether a Birth Defect War Inherited or Caused
by Toxin, S.F. EXAMINER, June 5, 1994, at Al. See also Wintz v. Northrop Corp., N. 95-C-815 (N.D. 111. Dec. 21, 1995),
notedin O.S.H. Rep. (BNA), Feb. 7,1996, at 1211 (granting summary judgment to employer and manufacturer (Kodak)
of chemical used in the workplace, where plaintiff-employee failed to prove that child's genetic discorder, Pradi-Willi
Syndrome, and other disabilities, were caused even in part by mother's exposure to bromide during her pregnancy).
171. For a more detailed explanation of fragile X syndrome, see supra note 13.
172. The teenage plaintiff was terrified of needles and had to be held down by his mother, which caused the child great
emotional trauma. Lehrman, supra note 170, at A]; see also Dodd-Anderson v. Stevens, Nos. 92-1015-MLB, 92-1016-
MLB, 1993 WL 273373 (D. Kan. May 4, 1993) (ordering genetic testing in medical malpractice action brought by child
with brain injury, but not expressly mentioning whether testing was for purpose of proving causation).
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possible way of limiting damages, testing intended to address damages should not
become permissible simply by alleging that it is to determine causation.
The next thing to consider is whether the plaintiffs current health status is
discoverable. Under established principles, if the plaintiff has a shortened life expectancy
because of an already manifested illness, such as heart disease, cancer, or some genetic
disorder, this fact is relevant and should be discoverable and admissible. A plaintiff with
a life expectancy of one year would reap a windfall if the defendant were forced to pay
lump sum damages based on a life expectancy of thirty years.
What about the discovery of predictive health information, genetic or otherwise? There
are two possibilities. The first involves the asymptomatic plaintiff who is unaware of any
genetic predisposition to a serious late-onset disorder. Medical records would be
uninformative, and ordering discovery through compelled genetic testing would be
tantamount to judicial sanctioning of a genetic fishing expedition. This testing would be
extremely difficult to justify, because it would require the plaintiff to confront
information he or she did not know previously and that he or she may not want to
know."' Furthermore, as discussed below, defendants, collectively, are in no worse a
position than they would be by using standard mortality tables.
Does the analysis change if the plaintiff previously underwent genetic testing in the
clinical setting or otherwise knew (such as through family health history) of his or her
genetic risks? In this situation, no problem exists with the plaintiff being involuntarily
confronted with new, possibly devastating information. Nevertheless, two other strong
policies demand that the information not be discoverable. First, the plaintiff should be
able to maintain the confidentiality of the information without disclosing such intimate
medical information to litigants and counsel, as well as other individuals, such as family
members, who may not have known of the original testing. Second, by permitting
discovery, individuals may be deterred from undergoing genetic testing because of fear
of the secondary consequences of having the information accessible. They also may be
deterred from bringing meritorious tort claims to avoid the disclosure of sensitive genetic
information.
The case for preventing discovery of already known genetic information is certainly
less compelling than that of discovering information that was previously unknown.
Nevertheless, practical problems link these two scenarios. Because plaintiffs have a great
economic incentive to withhold information about genetic predisposition, defendants
would have to assume that such information existed and consequently seek discovery of
genetic information on their own. 7 4
In summary, genetic testing to establish causation, narrowly defined and with a
protective order, should be permissible. As to damages, discovery of medical conditions,
including genetic disorders that already have manifested themselves, should also be
permissible. This includes gathering medical records, questioning the plaintiff and the
plaintiff's physicians at deposition, and, upon an appropriate showing of good cause,
compelling a medical examination. Discovery of general medical records should be
173. It is true that learning of genetic predisposition to a late-onset disorder may, in some instances and to some
people, be regarded as beneficial. Inasmuch as the individual chose not to avail himself or herself of the information,
however, any possible salutary effect cannot justify the intrusion.
174. This is analogous to the insurance principle of adverse selection, in which those at the greatest risk are most likely
to seek insurance. It is specifically to avoid adverse selection that insurance companies assert that they need to be able to
perform genetic testing. See generally Mark A. Rothstein, Genetics. Invurance, and the Ethics of Genetic Counseling, in
3 MOLECULAR GENETIC MEDICINE 159 (Theodore Friedmann ed., 1993).
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permitted even in the absence of any reason to suspect a serious disorder. Otherwise,
plaintiffs with extant but nonobvious disorders would receive a windfall. Without new
legislation, however, genetic information in general medical records could be revealed,
with the attendant negative implications for public policy previously discussed. Finally,
a compelled genetic test should not be permitted when the individual is asymptomatic,
regardless of whether the plaintiff has knowledge of a significant genetic risk. To be fair,
however, plaintiffs should be precluded from introducing evidence of genetic predictors
of longevity.
What are the costs and benefits of permitting or prohibiting this type of discovery? Part
II showed that the lump sum payment rule is outcome-neutral in the aggregate because,
theoretically over time, all plaintiffs will receive the same total amount of money from
all defendants that they would have been paid if all payments were made retroactively
instead of prospectively. The analysis does not change with the advent of new genetic
information. In fact, if one adds the costs of genetic testing and litigating the issue of life
expectancy, defendants in the aggregate will be worse off if discovery of genetic
information and genetic testing were permitted. On the other hand, some defendants will
be much better off and, without restrictions on their ability to obtain genetic information,
many plaintiffs, regardless of their financial recoveries, will be in a much worse position.
The following three subsections present three alternatives to deal with the problem of
discovery of genetic information. The first alternative is a judicial solution, through an
expansive reading and liberal use of protective orders pursuant to Rule 26(c) of the
Federal Rules of Civil Procedure. The second option would enact a specific genetic
confidentiality statute. After discussing some existing confidentiality laws, the key
elements of a genetic confidentiality statute are presented in subsection VI.C.2. The third
option would enact legislation for the variable periodic payment of damages. The theory
is simple: If defendants paid plaintiffs for lost income for their working lives and
terminated payments if the plaintiff died prematurely because of a preinjury medical
condition, then there would be no need to discover the plaintiff's medical records and
discovery requests for genetic information could be denied as irrelevant.
B. Protective Orders Under Rule 26(c) of the Federal Rules
of Civil Procedure and State Law Analogs
Rule 26(c) of the Federal Rules of Civil Procedure authorizes the trial court to issue
a wide range of discovery orders for the protection of parties during the discovery
process.'" Similar provisions are found in the rules of civil procedure of virtually every
state. The movant must show that good cause exists to prevent the opposing party from
engaging in any form of discovery which would be an "annoyance, embarrassment,
oppression, or undue burden or expense" to the movant.'7 6 Rule 26(c) prohibits or limits
the disclosure of relevant information, and so acts as a "necessary safeguard" in a system
which permits virtually unlimited discovery. 7 7
175. FED. R. CIV. P. 26(c).
176. Id.
177. See United States v. Columbia Broadcasting Sys., Inc., 666 F.2d 364, 368-69 (9th Cir.), cert. denied, 457 U.S.
1118 (1982); 8 WRUGHT& MiLLt, supra note 104, § 2036. A motion for a protective order is generally filed by a party.
In one New York case, however, a hospital sought a protective order to prevent it from producing the plaintiff's mental
health records. The court eventually compelled the hospital to produce the records, but only after considering the hospital's
motion for a protective order, which was opposed by both the defendant and the plaintiff. Cynthia B. v. New Rochelle
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The movant bears the burden of proving the necessity of the protective order. 78 This
burden must be met by showing specific examples of the harms to be avoided and the
high likelihood that harm will occur."' In some cases, the courts will require an in camera
examination of the evidence before issuing a protective order. t0
A finding of "good cause" to issue a protective order depends on the facts of the case,
but the term "good cause" "generally signifies a sound basis or legitimate need to take
judicial action."'' Frequently, the courts will consider whether alternative means for
discovery are available.' 2 If so, then a protective order is more likely to be issued.
Although no cases have yet addressed the specific issue of discovery of genetic
information, it is clear that a trial court may issue a protective order to safeguard privacy.
In Seattle Times Co. v. Rhinehart,' the Supreme Court observed that abuse of pretrial
discovery "is not limited to matters of delay and expense; discovery also may seriously
implicate privacy interests of litigants and third parties."'84 The Court further noted:
"Although the Rule [26(c)] contains no specific reference to privacy or to other rights or
interests that may be implicated, such matters are implicit in the broad purpose and
language of the Rule."' 85
Rule 26(c) empowers the court to issue "any order which justice requires," including
"that the discovery not be had." When presented with a motion to limit discovery through
issuance of a protective order, the court should weigh the relative interests of the parties
seeking and opposing discovery, as well as the public interest. As demonstrated in Part
V, both the personal injury plaintiff's and the public's interests in preserving privacy and
preventing the discovery of confidential genetic information are substantial. They
outweigh the defendant's interest in discovering a genetic basis for limiting damages.
Thus, there are ample legal and equitable grounds for issuing a protective order.
C. Enacting a Genetic Privacy and Confidentiality Law
1. Specific Confidentiality Laws
Legislation affording statutory protection for a particular class of medical records is
not novel. Numerous states have enacted laws protecting the confidentiality of HIV
records. At the federal level, legislation protects the confidentiality of substance abuse
records and records of genetic research.
Hosp. Med. Ctr., 458 N.E.2d 363 (N.Y. Sup. Ct. 1983).
178. Glenmede Trust Co. v. Thompson, 56 F.3d 476,483 (3d Cir. 1995); Bridges v. Eastman Kodak Co., 850 F. Supp.
216, 223 (S.D.N.Y. 1994).
179. Cipollone v. Liggett Group, Inc., 785 F.2d 1108, 1121 (3d Cir. 1986), cerl. denied, 487 U.S. 976 (1987); Nestle
Foods Corp. v. Aetna Casualty & Sur. Co., 129 F.R.D. 483,486 (D.N.J. 1990); Grinnell Corp. v. Hackett, 70 F.R.D. 326,
334 (D.R.I. 1976).
180. See Swift v. Swift, 64 F.R.D. 440, 443 (E.D.N.Y. 1974). Although there is no time requirement in Rule 26(c),
the motion should be filed in a timely manner. Prior to 1970, Rule 30 of the Federal Rules of Civil Procedure required that
a motion for a protective order be "seasonably" made. The 1970 revision deleted any reference to time, but motions have
been denied on the basis of inexcusable delay in filing. See Nestle Foods, 129 F.R.D. at 487 (denying protective order filed
two months after discovery due); United States v. Panhandle E. Corp., 118 F.R.D. 346, 350-51 (D. Del. 1988) (denying
protective order filed three weeks after discovery due).
181. I8 re Alexander Grant & Co. Litig., 820 F.2d 352, 356 (1 th Cir. 1987).
182. United States v. Illinois Fair Plan Ass'n, 67 F.R.D. 659, 661 (N.D. Ill. 1975); Salingue v. Overturf, 647 N.E.2d
1068, 1070 (i1. App. Ct. 1995).
183. 467 U.S. 20 (1984).
184. Id. at 34-35.
185. Id. at 35 n.21.
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a. HIV Records
Nineteen states have laws that protect the confidentiality of HIV records.'86 As
explained by one court, "the purpose of [these laws] is to control the spread of the HIV
virus by encouraging the public to submit to voluntary testing through an assurance of
confidentiality."'8 7 Most of the states permit disclosure of the information pursuant to
court order upon a showing of "compelling need." Only the laws in Colorado and Idaho
have no "compelling need" exception. In most states with a compelling need exception,
by statute, the need for the information in civil litigation is sufficient. In other states,
such as Pennsylvania, compelling need must be determined by the court on an individual
basis.'88
Even in those states with confidentiality laws, some courts have recognized the
admissibility (and therefore the discoverability) of the plaintiff's HIV status for the
purpose of assessing damages in a personal injury action. For example, in Dwight B. v.
Board of Education of the City of Newburgh, the court noted:
In bringing this action plaintiff has placed into issue not only his past and present
medical condition, but seeks also to argue the permanency of his injuries. That anyone,
let alone a young boy, has tested HIV positive, is a cause for great sadness: However,
suppressing this information from a jury which is charged with judging his medical
condition and, if appropriate, placing an award based on life expectancy, would not
serve the interests of justice, and would certainly violate defendant's right to a fair
trial. 89
HIV confidentiality laws seek to prevent the spread of infection. If confidentiality is
assured, at-risk individuals will be more likely to undergo testing. Those who test
positive will also be more likely to take precautions against transmission of the infection.
Because the primary purpose of these laws is to promote public health, the courts have
easily subordinated the laws' secondary interest in confidentiality to the search for truth
in litigation.9'
186. See ALA. CODE § 22-11A-54 (1995); ARiz. REV. STAT. ANN. § 36-665(B) (1993); CoLO. REV. STAT. ANN. §
25-4-1404 (West 1990&Supp. 1995); CONN. GEN. STAT. ANN. § 19a-583(10)(A) (West Supp. 1995); DEL. CODE ANN.
tit. 16, § 1203(a)(10) (1995); GA. CODEANN. § 24-9-47(s) (1995); ILL. ANN. STAT. ch. 410, para. 305/9 (Smith-Hurd
1993); IOWA CODE ANN. § 141.23(1)(g) (West 1989 & Supp. 1995); KY. REV. STAT. ANN. § 214.181.(5)(c)(9)(a)
(Miehie/Bobbs-Merrill 1995); LA. REV. STAT. ANN. § 40:1300.15(BX1) (West 1992); MICH. COMP. LAWS ANN. §
333.5131(3Xa) (West 1992); N.Y. PUB. HEALTH LAw § 2785 (MeKinney 1993 & Supp. 1996); N.C. GEN. STAT. § 130A-
143(6) (1995); OHIo REV. CODE ANN. § 3701.243(C)(1)(b) (Anderson 1995); OKLA. STAT. ANN. tit. 63, § 1-502.2(A)
(West Supp. 1996); 35 PA. CONS. STAT. ANN. § 7608(b) (1993); TEX. HEALTH & SAFETY CODE ANN. § 81.103(b)(4)
(West 1992); W. VA. CODE § 16-3C-3(9) (1995).
187. In re Application of Multimedia KSDK, Inc., 581 N.E.2d 911, 912 (III. App. Ct. 1991).
188. "[The court shall weigh the need for disclosure against the privacy interest of the individual and the public
interest which may be harmed by disclosure." PA. STAT. ANN. tit. 35, § 7608(c).
189.600 N.Y.S.2d 414,415 (Sup. Ct. 1993) (finding that defendant was entitled to discovery of plaintiffs HIV status);
see also Agosto v. Trusswal Sys. Corp., 142 F.R.D. 118 (E.D. Pa. 1992).
190. See generally Harold Edgar & Hazel Sandomire, Medical Priracy Issues in the Age of AIDS: Legislative
Options, 16 AM. J.L. & MED. 155 (1990); Roger Daughty, Comment, The Confidentiality ofHlV-RelatedInformaion:
Responding to the Resurgence of Aggressive Public Health Interventions in the AIDS Epidemic, 82 CAL. L. REV. 11
(1994).
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b. Substance Abuse Treatment Records
To encourage individuals to participate in substance abuse treatment programs, federal
law provides that any federally directed or federally funded program must ensure the
confidentiality of patient records. 19' Disclosure is permitted without the consent of the
individual in three situations: (1) to medical personnel in a bona fide medical emergency;
(2) to qualified personnel for conducting scientific research or program audits, as long
as the records are not in a personally identifiable form; and (3) upon a court order if good
cause is shown, which includes "the need to avert a substantial risk of death or serious
bodily harm."'92
Of the three exceptions, the good cause provision is the most vague. There is no
evidence, however, that this exception has been used to justify any wide-scale release of
confidential information. For example, courts have found good cause to release records
where a psychotherapist was being investigated for billing fraud;'93 where a defendant
convicted of heroin distribution was required to participate in a drug treatment program
as a condition of probation;' 9' and where an administratrix sought to recover for an
arrestee's death while in custody and defendants requested medical records to determine
whether drug use caused the death.' Conversely, a court did not find good cause when
a putative father in a paternity proceeding sought to obtain the natural mother's drug
treatment records to attack her credibility.
96
c. Records of Medical Research
The Public Health Service Act, as amended in 1988, contains a provision protecting
the privacy of individuals who are research subjects. 9 ' The Secretary of Health and
Human Services is authorized to issue a certificate of confidentiality to researchers
engaged in "biomedical, behavioral, clinical, or other research ... to protect the privacy
of individuals who are the subject of such research."' 99
Significantly, the ability to assert the confidentiality protection rests exclusively with
the researchers, who must seek the certificate from the Secretary and resist disclosure of
the research records. "Persons so authorized to protect the privacy of such individuals
may not be compelled in any Federal, State, or local, civil, criminal, administrative,
legislative, or other proceedings to identify such individuals."'"
191. The statute provides, in relevant part:
Records of the identity, diagnosis, prognosis, or treatment of any patient which are maintained in
connection with the performance of any program or activity relating to substance abuse education,
prevention, training, treatment, rehabilitation, or research, which is conducted, regulated, or directly or
indirectly assisted by any department or agency of the United States shall, except as provided in
subsection (e), be confidential and be disclosed only for the purposes and under the circumstances
expressly authorized under subsection (b).
42 U.S.C. § 290dd-2(a) (1994).
192. Id. § 290dd-2(b)(2).
193. In re August, 1993 Regular Grand Jury, 854 F. Supp. 1380, 1387 (S.D. Ind. 1994).
194. United States v. Hopper, 440 F. Supp. 1208, 1210-11 (N.D. III. 1977).
195. O'Boyle v. Jensen, 150 F.R.D. 519, 520-21 (M.D. Pa. 1993).
196. Commissioner of Social Servs. v. David R.S., 436 N.E.2d 451, 454-56 (N.Y.), rev'don other grounds, 439
N.E.2d 396 (N.Y. 1982).
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The rationale for this legislation is easy to understand, and it parallels the need for
protection of genetic records in the clinical setting. Without this protection, individuals
may be reluctant to participate in medical research due to possible adverse personal
consequences. 20  Moreover, the statute does not merely prohibit researchers from
disclosing the information; it also bars court-ordered disclosure in legal proceedings. This
is precisely the type of protection needed for genetic records.
2. Key Elements of a Genetic Privacy and
Confidentiality Law
a. All Genetic Records Must Be Kept Separate
from Other Medical Records
This provision requires that all health care providers who generate or maintain genetic
records store them apart from other medical records. Such a provision promotes
confidentiality and prevents the disclosure of genetic records when other health records
are released. The idea of storing sensitive medical records in separate files has been used
successfully in other contexts. 20'
Defining the term "genetic" in any genetic confidentiality statute would be a
conceptually difficult, although unavoidable, task. As a scientific matter, any attempt to
distinguish genetic medical records from nongenetic medical records is admittedly
imprecise. Nevertheless, it is clear that certain predictive genetic information which, if
disseminated, is likely to cause stigma, embarrassment, discrimination, and loss of esteem
should be protected from disclosure.
One may choose from several models in formulating a definition of the term "genetic."
A number of state legislatures have already enacted laws to prevent discrimination in
employment20 2 and insurance20 3 on the basis of genetic information or genetic testing. The
most comprehensive definition is found in California:
"Genetic characteristics" as used in this section means any scientifically or medically
identifiable gene or chromosome, or alteration thereof, that is known to be a cause of
a disease or disorder, or determined to be associated with a statistically increased risk
of development of a disease or disorder, that is presently not associated with any
symptoms of any disease or disorder .21
200. The original version of the statute applied only to research involving the use of illicit substances, but it was
difficult to find research subjects who were willing to admit that they had engaged in unlawful conduct. The 1988
amendment broadened the protection to all forms of biomedical research, thereby recognizing that negative consequences
could attach to research subjects' lawful activities as well. See generally Charles L. Earley & Louise C. Strong,
Certificates of Confidentiality: A Valuable Toal for Protecting Genetic Data, 57 AM. J. HUM. GENETIcs 727 (1995).
201. For example, psychiatric records are often stored separately from other medical records. Also, § 12112(d)(3) of
the Americans with Disabilities Act, 42 U.S.C. § 12101-12213 (1994 & Supp. 1995), provides that covered employers
must store all employee medical records in separate files (not with personnel files), which must be kept confidential.
Similar provisions are contained in state disability discrimination laws.
202. See FLA. STAT. ANN. § 448.075 (West 1981 & Supp. 1996); IOWA CODE ANN. § 729.6 (West 1993); LA. REv.
STAT. ANN. § 23:1002 (West 1985); N.H. REV. STAT. ANN. ch. 141-H (Supp. 1995); NJ. STAT. ANN. § 10:5-5(y)-(cc)
(West 1993 & Supp. 1995); N.Y. CIrv. RIGHTS LAW § 48-a (McKinney 1992); N.C. GEN. STAT. § 95-28.1 (1995); OR.
REV. STAT. § 659.227 (1995); R.I. GEN. LAWS § 28-6.7-1 (1995); WIs. STAT. ANN. § 111.372 (West Supp. 1995).
203. ARIZ. REV. STAT. ANN. § 20-448 (1990 & Supp. 1996); CAL HEALTH & SAETY CODE § 1374.7(a) (West Supp.
1995); COLO. REV. STAT. ANN. § 10-3-I 104.7(3)(b) (West Supp. 1995); GA. CODE ANN. § 33-54-3 to -4 (Supp. 1995);
MD. ANN. CODE art. 48A, § 223 (1994); MONT. CODE ANN. § 33-18-206(4), (5Xc) (1995); OHIO REv. CODE ANN. §
1742.42 (Anderson Supp. 1995); OR. REV. STAT. § 746.135(3) (1995); WIs. STAT. ANN. § 631.89(1) (West 1995).
204. CAL. HEALTH & SAFETY CODE § 1374.7(c) (West Supp. 1996).
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The significance of this definition is that it is not linked to "genetic testing" or any
specific genetic diseases or traits. A broad definition of "genetic" better protects against
a wide range of possible forms of discrimination, including that based on family histories.
b. All Genetic Information Disclosures, Not to
Health Care Providers, Are Limited to the
Individual Whose Records Are Involved
No release authorizing disclosure of these records to any party other than the person
whose genetic records are involved should be permitted except under the following
circumstances: First, where testing is appropriately authorized on children or incompetent
patients, parents or guardians may be notified of genetic information. Second, the
personal representative of the individual may be provided with the records in the event
the individual is deceased. Third, genetic information may be provided to law
enforcement authorities and other designated agencies for purposes of identification,
provided that the release is pursuant to legal process and the individual is unavailable for
testing.
Such a provision, with only narrow exceptions, limits disclosure of genetic information
to anyone other than the individual. The individual cannot sign a release authorizing
disclosure of the records to a third party.
c. Genetic Records Are Not Subject to Subpoena
The statute must expressly provide that genetic records are not subject to subpoena.
Without such a provision, the statute would have little value. This provision also permits
the health care provider or other custodian of genetic records to resist disclosure.
In 1995, Oregon enacted the first comprehensive genetic privacy legislation. 25 Among
other provisions, "a person may not disclose or be compelled, by subpoena or any other
means, to disclose.., genetic information about the individual in a manner that permits
identification of the individual.""2 6 An exception is made, however, for disclosures
pursuant to a specific court order in civil litigation,0 7 and, as such, this provision does
not satisfy the concerns set forth in this Article.
d. Prohibiting Disclosure of Genetic Records
to Establish Plaintiff's Future Lost Income in a
Civil Action
This provision would prohibit conditioning any civil action on discovery of plaintiff's
genetic records. It is designed to prevent plaintiffs from being ordered to produce their
own genetic records. Although the above provision is limited to civil litigation, similar
language could be used to prohibit the conditioning of employment or insurance on the
disclosure of genetic information. Significantly, the provision is specifically limited to
the issue of damages; it allows defendants to discover genetic information necessary to
205. OR. REV. STAT. § 659.700-659.720 (1995).
206. Id. § 659.720(1).
207. Id. § 659.720(1)(b).
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demonstrate that the plaintiffs injuries were caused by genetic factors rather than by any
action of the defendant.
To obtain causation-related genetic discovery, the defendant would have to
demonstrate a reasonable basis for believing that the plaintiff's alleged injuries could be
the result of genetic factors. When discovery is ordered, the plaintiff would have a right
to require that defendant's experts and counsel be subject to a protective order, that the
information be reviewed in camera, and that the record be sealed.
e. Prohibition of Compelled Genetic Testing
The statute should expressly prohibit the compelled genetic testing of any individual
in civil litigation.
D. Variable Periodic Payment of Damages
If payment to the plaintiff were made in installments for the duration of the plaintiff's
life, as opposed to a lump sum payment, it would be unnecessary to estimate the life
expectancy or work life expectancy of the plaintiff. Payments would simply terminate on
the plaintiff's death. Under such a payment system, therefore, predictions of the
plaintiff's future health status and life expectancy, including those based on the
plaintiff's genotype, would be irrelevant. Such a system would differ markedly from the
current lump sum payment system and the current statutory enactments providing for
periodic payments of damages.
As mentioned earlier, lump sum payments have been used at common law for centuries.
Nevertheless, periodic payments have been used successfully in other countries.2"' There
are three main arguments supporting periodic payments: (1) they more accurately reflect
the plaintiff's actual loss; (2) they avoid the dissipation of resources by the plaintiff; and
(3) they have more advantageous tax consequences for the plaintiff.0 9 There are also
three main arguments in favor of the continued use of the lump sum payment rule: (1)
simplicity; (2) efficiency; and (3) finality.210
Most states have enacted statutes providing for the optional use of periodic payments
of damages. 21 In general, opposition from both plaintiffs (who tend to want immediate
payment in full)2 12 and insurance companies (who dislike the uncertainty of carrying
forward obligations for an unknown period of years) has curbed the use of these laws. As
currently drafted, however, the statutes are inadequate to relieve the pressure to discover
genetic records.
The Uniform Periodic Payment of Judgments Act ("UPPJA"), 1 provides that, in a
claim for future economic loss over $100,000, either party may elect a periodic payment
208. See generally John G. Fleming, Damages: Capital or Rent?, 19 U. TORONTO L. 295 (1969); Ferdinand F.
Stone, Separate Trials, Declaratory Rulings and Installment Damages: A Comparative Study, 35 TUL. L. REV. 597 (1961).
209. See Marcus L. Plant, Periodic Payment ofDamagesfor Personal Injury, 44 LA. L. REV. 1327 (1984); Barbara
Ba]zer Kolbach, Comment, Variable Periodic Payments of Damages: An Alternative to Lump Sum Awards, 64 IOWA L.
REV. 138 (1978).
210. See Samuel A. Rea, Jr., Lump-Sum Versus Periodic Damage Awards, 10 J. LEGAL STUD. 131 (1981).
211. See Henderson, supra note 80.
212. See, e.g., Philip H. Corboy, Structured htstice: Compulsory Periodic Payment ofJudgments, 66 A.B.A. J. 1524,
1524 (1980).
213. UNIF. PERIODIC PAYMENT OF JUDGMENTS ACT §§ 1-24, 14 U.L.A. 11 (Supp. 1995).
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award rather than a lump sum judgment."' If a party elects to receive a periodic payment
award, the court will ask the jury to specify any past damages in a lump sum, any future
noneconomic loss in a lump sum, and future damages for medical expenses and other
economic loss.215 The jury must then determine the annual periods over which the claims
for medical expenses and other economic loss will accrue. 216 More importantly, the jury
must determine how long the claimant would have lived but for the injury. Virtually all
of the current periodic payment statutes still require litigation over the plaintiffs
preinjury life expectancy.
The problem with current periodic payment statutes is that they establish a lump sum
calculation of damages using a periodic payment mechanism. Only a system of variable
payments would eliminate the need for an estimate of life expectancy. Although plaintiffs
tend to view periodic payment statutes as pro-defendant, plaintiffs may be willing to elect
periodic payments in exchange for a ban on discovery of genetic information." 7
Defendants would be able to avoid the problem of overcompensation and the cost of
proving life expectancy if a feasible, efficient system for variable periodic payments were
developed.
CONCLUSION
Professor John G. Fleming began a 1962 law review article on damages with the
following sentence:
Significant and continuing advances by contemporary medicine in diagnostic and
clinical skills have made it increasingly more possible and common to venture a
prognosis of diminished life expectancy for victims of disease and accident, sufficiently
reliable to meet the conventional legal standard of proof on a balance of probabilities.,
Undoubtedly, Professor Fleming was referring to predictions of life expectancy based on
currently manifested medical conditions. He probably could not have imagined that by
the end of the century, the DNA in a single drop of blood could be used to predict the
future health status of an asymptomatic individual.
In personal injury litigation, blindly permitting the discovery of unlimited amounts of
medical information for determining damages does not serve justice. The incantation of
the "search for truth" in discovery cannot be used to override all other interests. It is true
that a wide range of personal information, including facts about income and relationships,
is routinely discovered in civil litigation. Yet, substantial and unique public policy
interests weigh in favor of protecting the privacy and confidentiality of sensitive genetic
information. Individuals should not be deterred from asserting valid legal claims due to
concerns about the needlessly intrusive discovery of genetic information.
No cases have yet been reported in which defendants have sought to discover genetic
information or to perform genetic testing on a personal injury plaintiff solely for use in
assessing damages. Nevertheless, such an action will inevitably occur. Indeed, it is
surprising that it has not occurred already. The financial stakes for individual defendants
214. Id. § 2.
215. Id'§-4.
216. Id.
217. Any statute would need to include provisions to protect the plaintiff in the event of the defendant's bankruptcy
or insolvency.
218. John G. Fleming, The Lost Years: A Problem in the Computation andDistribution of Damages, 50 CAL. L. REv.
598, 598 (1962).
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are too high, and the adversarial culture of personal injury litigation too ingrained, to
assume that genetic information will not mutate from the criminal to the civil courts.
Motions to compel production of genetic records or to compel genetic testing are not a
matter of "whether," but of "when." Therefore, time is of the essence in addressing these
concerns.
This Article has presented three ways to prevent the use of a personal injury plaintiff's
genetic profile in assessing damages. One of the alternatives is judicial, while two are
legislative. The judicial solution is the easiest to implement. Judges in the federal and
state courts already have the power to prevent burdensome and embarrassing discovery
by issuing protective orders. The problem is that, even in the most favorable scenario, it
will take years to achieve any degree of consensus in the courts that discovery of a
personal injury plaintiff's genetic profile solely for the purposes of assessing damages
is impermissible. It is more likely that there will be a split of authority and many
jurisdictions will have no authoritative position.
The second alternative involves enacting legislation to protect the confidentiality of
genetic information. This approach has the virtue of providing protections to individuals
beyond the narrow realm of civil litigation. However, there are several problems with this
alternative. First, without a federal law, there will be gaps in the protections afforded by
the states. Second, legislatures will face difficulties in agreeing on a definition of
"genetic" to be used in the statute. Third, drafters must reconsider the issue of whether
genetic confidentiality legislation should provide an exception to court-ordered
discovery.
The third alternative is to modify the system of damages in personal injury litigation
to adopt variable periodic payment of damages. This approach has the virtue of being a
more comprehensive response to the problem, as well as obviating the need to define
"genetic." On the other hand, merely changing the system of damages in personal injury
litigation will not prohibit disclosures beyond litigation. Moreover, this alternative is
unlikely to be adopted, because its sweep is so broad and because it is certain to engender
intense opposition from both plaintiffs' and defendants' counsel.
These three alternatives are neither mutually exclusive nor exhaustive of the possible
approaches to prevent excessive genetic probing in civil litigation. Nevertheless, various
measures need to be carefully considered and expeditiously implemented before human
geneticists become regular consultants and witnesses in tort litigation.
And what would happen to Dr. Jane Smith, the hypothetical plaintiff of this Article's
Introduction, under today's law? Undoubtedly, the defendant may obtain Smith's medical
records, because her physical condition is relevant to past and future medical expenses.
The court compelling production of her medical records could exclude, on public policy
grounds, all predictive genetic information. However, it is an open question how many
courts are prepared to exclude such information.
If health care providers stored all of Dr. Smith's genetic records separately, and if a
statute limiting their discoverability existed, this would permit discovery of her medical
records without discovery of her genetic records. Assuming her existing genetic records
are discoverable, genetic testing of Dr. Smith could be barred on public policy grounds,
regardless of whether there is genetic test information in her medical records. A
protective order under Rule 26(c) of the Federal Rules of Civil Procedure could be sought
to prevent the "burdensome" and "embarrassing" production of her genetic records,
depositions of Dr. Smith or her treating physicians regarding genetic information, or
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compelled genetic testing. Again, it is not clear whether courts would adopt this approach.
Finally, if the damages awarded to Dr. Smith were payable on a variable, periodic
basis, they would be paid when due, without regard for her predicted life expectancy or
work life expectancy. The defendant would pay and Dr. Smith would receive exactly the
amount of money which reflects her work life and life span.
Although Dr. Smith will no longer be able to practice neurosurgery, perhaps she could
take additional training in medical genetics. A need exists for trained medical geneticists
in providing health care, where the goal is solely to improve the health of the patient.
